0001558370-23-018665.txt : 20231113 0001558370-23-018665.hdr.sgml : 20231113 20231113060940 ACCESSION NUMBER: 0001558370-23-018665 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 231394714 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 10-Q 1 mist-20230930x10q.htm 10-Q
0001408443--12-312023Q3false3348178734286002A800-0000000UnlimitedUnlimited95772570.25P4Y8518257334817870.02780.040.02780001408443us-gaap:CommonStockMember2022-07-012022-09-300001408443us-gaap:CommonStockMember2022-01-012022-09-300001408443us-gaap:CommonStockMember2023-07-012023-09-300001408443us-gaap:EmployeeStockMember2023-01-012023-09-300001408443us-gaap:CommonStockMember2023-01-012023-09-300001408443mist:EmployeeStockPurchasePlanMember2023-01-012023-09-300001408443us-gaap:RetainedEarningsMember2023-09-300001408443us-gaap:AdditionalPaidInCapitalMember2023-09-300001408443us-gaap:RetainedEarningsMember2023-06-300001408443us-gaap:AdditionalPaidInCapitalMember2023-06-3000014084432023-06-300001408443us-gaap:RetainedEarningsMember2022-12-310001408443us-gaap:AdditionalPaidInCapitalMember2022-12-310001408443us-gaap:RetainedEarningsMember2022-09-300001408443us-gaap:AdditionalPaidInCapitalMember2022-09-300001408443us-gaap:RetainedEarningsMember2022-06-300001408443us-gaap:AdditionalPaidInCapitalMember2022-06-3000014084432022-06-300001408443us-gaap:RetainedEarningsMember2021-12-310001408443us-gaap:AdditionalPaidInCapitalMember2021-12-310001408443mist:InducementPlanMember2023-01-012023-09-300001408443mist:RestatedShareOptionPlan2011Member2022-12-310001408443mist:InducementPlanMember2022-12-310001408443mist:EquityIncentivePlan2019Member2022-12-310001408443mist:InducementPlanMember2022-09-300001408443mist:RestatedShareOptionPlan2011Member2021-12-310001408443mist:EquityIncentivePlan2019Member2021-12-310001408443mist:RestatedShareOptionPlan2011Member2023-01-012023-09-300001408443mist:RestatedShareOptionPlan2011Member2022-01-012022-09-300001408443mist:RestatedShareOptionPlan2011Member2023-09-300001408443mist:Plans2011And2019And2021InducementMember2023-09-300001408443mist:RestatedShareOptionPlan2011Member2022-09-300001408443mist:Plans2011And2019And2021InducementMember2022-09-300001408443mist:EquityIncentivePlan2019Member2022-09-300001408443us-gaap:EmployeeStockMember2023-09-300001408443us-gaap:EmployeeStockOptionMembermist:RestatedShareOptionPlan2011Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-01-012023-09-300001408443us-gaap:EmployeeStockOptionMembermist:RestatedShareOptionPlan2011Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-09-300001408443us-gaap:EmployeeStockOptionMembermist:EquityIncentivePlan2019Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-01-012023-09-300001408443us-gaap:EmployeeStockOptionMembermist:EquityIncentivePlan2019Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-09-300001408443us-gaap:EmployeeStockOptionMembermist:RestatedShareOptionPlan2011Member2023-01-012023-09-300001408443us-gaap:EmployeeStockOptionMembermist:EquityIncentivePlan2019Member2023-01-012023-09-300001408443us-gaap:RetainedEarningsMember2023-07-012023-09-300001408443us-gaap:RetainedEarningsMember2023-01-012023-09-300001408443us-gaap:RetainedEarningsMember2022-07-012022-09-300001408443us-gaap:RetainedEarningsMember2022-01-012022-09-300001408443us-gaap:CommonStockMember2023-09-300001408443us-gaap:CommonStockMember2023-06-300001408443us-gaap:CommonStockMember2022-12-310001408443mist:PreFundedWarrantMember2022-12-310001408443us-gaap:CommonStockMember2022-09-300001408443us-gaap:CommonStockMember2022-06-300001408443us-gaap:CommonStockMember2021-12-310001408443mist:PreFundedWarrantMember2021-12-310001408443mist:InducementPlanMember2023-09-300001408443mist:EquityIncentivePlan2019Member2023-09-300001408443mist:EmployeeStockPurchasePlanMember2023-09-300001408443mist:EquityIncentivePlan2019Member2023-01-010001408443mist:EmployeeStockPurchasePlanMember2023-01-010001408443mist:EquityIncentivePlan2019Member2022-07-050001408443mist:EquityIncentivePlan2019Member2022-01-010001408443mist:PreFundedWarrantMember2023-09-300001408443mist:PreFundedWarrantMember2023-06-300001408443mist:PreFundedWarrantMember2022-09-300001408443mist:PreFundedWarrantMember2022-06-3000014084432022-09-3000014084432021-12-310001408443us-gaap:StockCompensationPlanMember2023-01-012023-09-300001408443us-gaap:StockCompensationPlanMember2022-01-012022-09-300001408443mist:RtwInvestmentsLpMemberus-gaap:ConvertibleDebtMembermist:StrategicFinancingAgreementsMember2023-07-012023-09-300001408443mist:RtwInvestmentsLpMemberus-gaap:ConvertibleDebtMembermist:StrategicFinancingAgreementsMember2023-01-012023-09-300001408443us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001408443us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001408443mist:CommercialActivitiesMember2023-07-012023-09-300001408443us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001408443us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001408443mist:CommercialActivitiesMember2023-01-012023-09-300001408443us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001408443us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001408443mist:CommercialActivitiesMember2022-07-012022-09-300001408443us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001408443us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001408443mist:CommercialActivitiesMember2022-01-012022-09-300001408443us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001408443us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001408443us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001408443us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001408443mist:PreFundedWarrantMember2023-01-012023-09-300001408443mist:InducementPlanMember2022-01-012022-09-300001408443mist:EquityIncentivePlan2019Member2022-01-012022-09-300001408443mist:RestatedShareOptionPlan2011Member2022-01-012022-01-010001408443mist:EquityIncentivePlan2019Member2023-07-012023-09-300001408443mist:EquityIncentivePlan2019Member2023-01-012023-09-300001408443mist:RtwInvestmentsLpMembersrt:MinimumMembermist:AggregateNetSalesAbove500MillionMembermist:StrategicFinancingAgreementsMember2023-03-272023-03-270001408443mist:RtwInvestmentsLpMembersrt:MaximumMembermist:AggregateNetSalesUpTo800MillionMembermist:StrategicFinancingAgreementsMember2023-03-272023-03-270001408443mist:RtwInvestmentsLpMembermist:AggregateNetSalesAbove800MillionMembermist:StrategicFinancingAgreementsMember2023-03-272023-03-270001408443mist:RtwInvestmentsLpMembermist:StrategicFinancingAgreementsMember2023-03-272023-03-270001408443mist:RtwInvestmentsLpMemberus-gaap:ConvertibleDebtMembermist:StrategicFinancingAgreementsMember2023-03-292023-03-290001408443mist:RtwInvestmentsLpMemberus-gaap:ConvertibleDebtMembermist:StrategicFinancingAgreementsMember2023-09-300001408443mist:RtwInvestmentsLpMemberus-gaap:ConvertibleDebtMembermist:StrategicFinancingAgreementsMember2023-03-290001408443mist:RtwInvestmentsLpMember2023-03-2200014084432023-07-012023-09-3000014084432022-07-012022-09-3000014084432022-01-012022-09-3000014084432022-01-012022-12-310001408443mist:RtwInvestmentsLpMember2023-03-222023-03-220001408443mist:RtwInvestmentsLpMembermist:AggregateNetSalesUpTo500MillionMembermist:StrategicFinancingAgreementsMember2023-03-272023-03-2700014084432023-09-3000014084432022-12-3100014084432023-11-1300014084432023-01-012023-09-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesmist:item

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to

Commission File Number: 001-38899

Milestone Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

Québec

    

Not applicable

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1111 Dr. Frederik-Philips Boulevard, Suite 420

Montréal, Québec CA H4M 2X6

(514) 336-0444

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Shares

MIST

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of November 13th, 2023, the registrant had 33,483,111 common shares, no par value per share, outstanding.

Table of Contents

Page

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

1

PART I.

FINANCIAL INFORMATION

3

Item 1.

Financial Statements (Unaudited)

3

Condensed Consolidated Balance Sheets

3

Condensed Consolidated Statements of Loss

4

Condensed Consolidated Statements of Shareholders’ Equity

5

Condensed Consolidated Statements of Cash Flows

6

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

PART II.

OTHER INFORMATION

28

Item 1.

Legal Proceedings

28

Item 1A.

Risk Factors

28

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

30

Item 3.

Defaults Upon Senior Securities

30

Item 4.

Mine Safety Disclosures

30

Item 5.

Other Information

30

Item 6.

Exhibits

31

“Milestone Pharmaceuticals” and the Milestone logo appearing in this Quarterly Report on Form 10-Q are unregistered trademarks of Milestone Pharmaceuticals Inc. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Quarterly Report on Form 10-Q may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.

This Quarterly Report on Form 10-Q contains references to United States dollars and Canadian dollars. All dollar amounts referenced, unless otherwise indicated, are expressed in United States dollars. References to “$” are to United States dollars and references to “C$” are to Canadian dollars.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q, regarding, among other things:

the initiation, timing, progress and results of our current and future clinical trials of etripamil, including our Phase 3 clinical trials of etripamil for the treatment of paroxysmal supraventricular tachycardia, our Phase 2 clinical trial of etripamil for the treatment of atrial fibrillation with rapid ventricular rate, and of our research and development programs;
our plans to develop and commercialize etripamil and any future product candidates;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our ability to develop and, if approved by regulatory authorities, commercialize etripamil in China and Taiwan through our license agreement with Ji Xing Pharmaceuticals;
our ability to establish collaborations or obtain additional funding;
our ability to obtain regulatory approval of our current and future product candidates;
our expectations regarding the potential market size and the rate and degree of market acceptance of etripamil and any future product candidates;
our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources;
the implementation of our business model and strategic plans for our business, etripamil and any future product candidates;
our intellectual property position and the duration of our patent rights;

1

developments or disputes concerning our intellectual property or other proprietary rights;
our expectations regarding government and third-party payer coverage and reimbursement;
our ability to compete in the markets we serve;
the impact of government laws and regulations;
developments relating to our competitors and our industry; and
other factors that may impact our financial results.

The foregoing list of risks is not exhaustive. Other sections of this Quarterly Report on Form 10-Q and the section titled "Risk Factors" previously disclosed in Part I, Item 1A. in our Annual Report on Form 10-K may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled "Risk Factors" previously disclosed in Part I, Item 1A. in our Annual Report on Form 10-K, filed with the SEC and under Milestone’s SEDAR profile at www.sedarplus.com on March 29, 2023, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

2

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Milestone Pharmaceuticals Inc.

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands of US dollars, except share data)

    

September 30, 2023

    

December 31, 2022

Assets

  

 

  

Current assets

 

  

Cash and cash equivalents

$

9,879

 

$

7,636

Short-term investments

65,867

56,949

Research and development tax credits receivable

569

 

331

Prepaid expenses

6,961

 

6,005

Other receivables

1,521

 

882

Total current assets

84,797

 

71,803

Operating lease assets

2,047

2,423

Property and equipment

272

 

257

Total assets

$

87,116

 

$

74,483

Liabilities, and Shareholders' Equity

  

 

  

Current liabilities

  

 

  

Accounts payable and accrued liabilities

$

7,584

 

$

5,644

Operating lease liabilities

530

 

495

Total current liabilities

8,114

 

6,139

Operating lease liabilities, net of current portion

1,583

 

1,996

Senior secured convertible notes

48,915

Total liabilities

58,612

 

8,135

Shareholders’ Equity

 

  

Common shares, no par value, unlimited shares authorized 33,481,787 shares issued and outstanding as of September 30, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022

260,502

 

273,900

Pre-funded warrants - 9,577,257 issued and outstanding as of September 30, 2023 and 8,518,257 as of December 31, 2022

48,459

34,352

Additional paid-in capital

31,958

 

24,437

Accumulated deficit

(312,415)

 

(266,341)

Total shareholders’ equity

28,504

 

66,348

Total liabilities and shareholders’ equity

$

87,116

 

$

74,483

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

3

Milestone Pharmaceuticals Inc.

Condensed Consolidated Statements of Loss (Unaudited)

(in thousands of US dollars, except share and per share data)

Three months ended September 30, 

Nine months ended September 30, 

    

2023

   

2022

     

2023

   

2022

Revenue

$

 

$

1,500

$

1,000

 

$

1,500

Operating expenses

 

 

 

Research and development, net of tax credits

 

6,721

 

9,826

25,600

 

29,251

General and administrative

 

4,227

 

4,034

12,561

 

11,595

Commercial

 

4,412

 

2,670

10,137

 

6,537

Loss from operations

 

(15,360)

 

(15,030)

(47,298)

 

(45,883)

Interest income

 

1,120

 

474

2,921

 

672

Interest expense

(841)

(1,697)

Net loss and comprehensive loss

 

$

(15,081)

 

$

(14,556)

$

(46,074)

 

$

(45,211)

Weighted average number of shares and pre-funded warrants outstanding, basic and diluted

42,973,160

42,491,787

42,920,620

42,339,123

Net loss per share, basic and diluted

 

$

(0.35)

 

$

(0.34)

$

(1.07)

 

$

(1.07)

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

4

Milestone Pharmaceuticals Inc.

Condensed Consolidated Statements of Shareholders’ Equity (Unaudited)

(in thousands of US dollars, except share data)

Common Shares

Pre-funded warrants

    

Number
of shares

    

Amount

    

Number
of warrants

    

Amount

    

Additional
paid-in
capital

    

Accumulated
deficit

    

Total

Balance as of June 30, 2022

30,005,884

$

252,236

12,327,780

$

52,941

$

20,090

$

(238,608)

$

86,659

Transactions in three-month period ended September 30, 2022

Net loss

(14,556)

(14,556)

Exercise of stock options

20,989

57

(29)

28

Share-based compensation

2,380

2,380

Issuance of common shares, net of issuance costs

361,236

2,644

2,644

Balance as of September 30, 2022

30,388,109

$

254,937

12,327,780

$

52,941

$

22,441

$

(253,164)

$

77,155

Balance as of June 30, 2023

33,363,971

$

260,169

9,577,257

$

48,459

$

29,114

$

(297,334)

$

40,408

Transactions in three-month period ended September 30, 2023

Net loss

(15,081)

(15,081)

Exercise of stock options

18,798

68

(28)

40

Share-based compensation

2,872

2,872

Employee stock purchase plan purchases

99,018

265

265

Balance as of September 30, 2023

33,481,787

$

260,502

9,577,257

$

48,459

$

31,958

$

(312,415)

$

28,504

Balance as of December 31, 2021

29,897,559

$

251,901

12,327,780

$

52,941

$

15,711

$

(207,953)

$

112,600

Transactions in nine-month period ended September 30, 2022

Net loss

(45,211)

(45,211)

Exercise of stock options

129,314

392

(175)

217

Share-based compensation

6,905

6,905

Issuance of common shares, net of issuance costs

361,236

2,644

2,644

Balance as of September 30, 2022

30,388,109

$

254,937

12,327,780

$

52,941

$

22,441

$

(253,164)

$

77,155

Balance as of December 31, 2022

34,286,002

$

273,900

8,518,257

$

34,352

$

24,437

$

(266,341)

$

66,348

Transactions in nine-month period ended September 30, 2023

Net loss

(46,074)

(46,074)

Exercise of stock options

112,779

324

(136)

188

Pre-funded warrants - Private Placement, net of issuance costs

1,059,000

14,107

14,107

Share-based compensation

7,657

7,657

Cancellation of common shares

(1,059,000)

(14,115)

(14,115)

Employee stock purchase plan purchases

142,006

393

393

Balance as of September 30, 2023

33,481,787

$

260,502

9,577,257

$

48,459

$

31,958

$

(312,415)

$

28,504

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

5

Milestone Pharmaceuticals Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands of US dollars)

Nine months ended September 30, 

2023

    

2022

Cash flows used in operating activities

Net loss

$

(46,074)

$

(45,211)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation of property and equipment

66

74

Amortization of debt costs

160

Accretion of investment discount

(79)

Non-cash interest expense related to debt

1,537

Share-based compensation expense

7,657

6,905

Changes in operating assets and liabilities:

Other receivables

(639)

(308)

Research and development tax credits receivable

(238)

161

Prepaid expenses

(956)

(759)

Operating lease assets and liabilities

(2)

47

Accounts payable and accrued liabilities

1,940

(516)

Net cash used in operating activities

(36,628)

(39,607)

Cash provided by (used in) investing activities

Acquisition of property and equipment

(81)

(162)

Acquisition of short-term investments

(95,839)

(62,947)

Redemption of short-term investments

87,000

23,000

Net cash used in investing activities

(8,920)

(40,109)

Cash provided by financing activities

Proceeds from exercise of options

188

217

Proceeds from issuance of senior secured convertible debt

50,000

Issuance of common shares, net of issuance costs

2,644

Pre-funded warrant issuance costs

(8)

Proceeds from employee stock purchase plan

393

Payment of debt issuance costs

(2,782)

Cash provided by financing activities

47,791

2,861

Net increase (decrease) in cash and cash equivalents

2,243

(76,855)

Cash and cash equivalents – Beginning of period

7,636

114,141

Cash and cash equivalents – End of period

$

9,879

$

37,286

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

6

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

1    Organization and Nature of Operations

Milestone Pharmaceuticals Inc. (Milestone or the Company) is a biopharmaceutical company incorporated under the Business Corporations Act (Québec). Milestone is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate, etripamil, is a novel, potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

2     Summary of Significant Accounting Policies

a)  Basis of Consolidation

The consolidated financial statements include the accounts of the Company and Milestone Pharmaceuticals USA, Inc. All intercompany transactions and balances have been eliminated.

b)  Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies

These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or “US GAAP”, and on a basis consistent with those accounting principles followed by the Company and disclosed in Note 2 of its most recent annual consolidated financial statements. Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with US GAAP have been omitted or condensed.  Accordingly, these unaudited interim condensed consolidated financial statements do not include all the information required for full annual financial statements, and therefore, should be read in conjunction with the annual consolidated financial statements and the notes thereto for the year ended December 31, 2022.

In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its balance sheet as of September 30, 2023, and its statements of loss and shareholders’ equity for the three and nine months ended September 30, 2023 and 2022 and its statements of cash flows for the nine months ended September 30, 2023 and 2022.

The condensed consolidated balance sheet as of December 31, 2022, was derived from audited annual consolidated financial statements, but does not contain all the footnote disclosures required by accounting principles generally accepted in the United States of America.

These unaudited interim condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.

The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to,

Estimates of the percentage of work completed of the total work over the life of an individual clinical trial in accordance with agreements established with contracted research organizations, or “CRO”, contracted

7

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

manufacturing organizations, or “CMO”, and clinical trial sites which in turn impact the research & development expenses.
Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.

c) Significant Risks and Uncertainties

The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements.  

Further, the Company may be impacted by general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international armed conflicts and overall fluctuations in the financial markets in the United States and abroad.

d) Recent Accounting Pronouncements

The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

e) Sources of Liquidity and Funding Requirements

The Company incurred operating losses and has experienced negative operating cash flows since its inception  and anticipates to continue to incur losses for at least the next several years. As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million. Management has evaluated the Company’s operating plan against its existing cash and cash equivalents and determined that the Company expects to be able to support its operations for at least the next 12 months from the date of issuance of these unaudited interim consolidated financial statements.

3     Revenues

The Company recorded no revenue for the three months ended September 30, 2023 and $1.0 million in revenue during the nine months ended September 30, 2023. This revenue is due to a milestone reached as a result of the successful initiation of a Phase 1 Clinical Trial of the product by or on behalf of Ji Xing for the treatment of paroxysmal supraventricular tachycardia, or “PSVT”, in the Territory. The Company recorded $1.5 million in revenue for the three and nine months ended September 30, 2022. This revenue was related to a milestone reached as a result of the first patient dosed in a Phase 3 Clinical Trial for the treatment of PSVT in the Territory. For details on the arrangement with Ji Xing, see Note 3 to our audited consolidated financial statements for the year ended December 31, 2022, filed on Form 10-K.

4     Short-term Investments

Short term investments are classified as held-to-maturity, are initially recognized at fair value and are subsequently accounted for at amortized cost. They are comprised of guaranteed investment certificates with a maturity greater than 90 days but less than one year and, as such, are classified as current assets.

8

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

5     Debt

On March 27, 2023, we entered into a note purchase agreement, or the “Note Purchase Agreement”, with RTW Investments LP and certain of its affiliates, or collectively, RTW.

On March 29, 2023, we closed the transactions contemplated by the Note Purchase Agreement, and issued and sold $50.0 million principal amount of 6.0% Convertible Senior Notes due 2029, or the “2029 Convertible Notes”, to the holders.

The 2029 Convertible Notes are senior secured obligations and are guaranteed on a senior secured basis by our wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc. Interest at the annual rate of 6.0% is payable quarterly in cash or, at our option, payable in kind for the first three years. The maturity date for the 2029 Convertible Notes is March 31, 2029, the “Maturity Date”. The obligations under the 2029 Convertible Notes are secured by substantially all of our and our subsidiary guarantor’s assets.

Each $1,000 of principal of the 2029 Convertible Notes (including any interest added thereto as payment in kind) is convertible into 191.0548 shares of our common shares, equivalent to an initial conversion price of approximately $5.23 per share, subject to customary anti-dilution and other adjustments. In addition, following a notice of redemption or certain corporate events that occur prior to the Maturity Date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2029 Convertible Notes in connection with such notice of redemption or corporate event.

On or after March 27, 2027, the 2029 Convertible Notes are redeemable by us, subject to certain conditions, if the closing sale price of the common shares exceeds 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

In accounting for the issuance of the Convertible Notes, the Company determined there were no embedded features, which require bifurcation between debt and equity components. As a result, the Convertible Notes are accounted for as a liability. As of September 30, 2023, the estimated fair value of the Convertible Notes was approximately $51.4 million.

The net carrying amount of the Convertible Note were as follows:

    

September 30, 2023

December 31, 2022

Original principal

 

$

50,000

$

Paid in kind (PIK) interest

1,537

Unamortized debt discount

(566)

Unamortized debt issuance costs

 

(2,056)

Total

 

$

48,915

$

9

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

The following table presents the total amount of interest cost recognized relating to the 2029 Convertible Notes (in thousands):

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Contractual interest expense

$

762

 

$

$

1,537

 

$

Amortization of debt discount

16

34

Amortization of debt issuance costs

63

 

126

 

Total interest expense

$

841

 

$

$

1,697

 

$

6    Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of the following:  

    

September 30, 2023

December 31, 2022

    

  

 

  

Trade accounts payable

 

$

1,855

$

2,263

Accrued compensation and benefits payable

 

2,426

2,573

Accrued research and development liabilities

 

2,051

404

Other accrued liabilities

 

1,252

404

Total

 

$

7,584

$

5,644

7      Shareholders’ Equity

Authorized Share Capital

The Company has authorized and issued common shares, voting and participating, without par value, of which unlimited shares were authorized and 33,481,787 shares were issued and outstanding as of September 30, 2023.

As of September 30, 2023, there were 1,463,936 common shares available for issuance under the Employee Stock Purchase Plan, or the “ESPP”. The Company has issued 142,006 shares of common stock pursuant to the ESPP as of September 30, 2023.

On March 22, 2023, the Company entered into an exchange agreement, or the “Exchange Agreement”, with entities affiliated with RTW, or the Exchanging Stockholders, pursuant to which the Company exchanged an aggregate of 1,059,000 shares of the Company’s common shares owned by the Exchanging Stockholders for pre-funded warrants, or the Exchange Warrants, to purchase an aggregate of 1,059,000 common shares, with an exercise price of $0.001 per share and no expiration date. The Exchange Warrants are exercisable immediately and no additional cash consideration was rendered in exchange for the warrants. A holder of the Exchange Warrants (together with its affiliates and other attribution parties) may not exercise any portion of an Exchange Warrant to the extent that immediately prior to or after giving effect to such exercise the holder, together with its affiliates, would beneficially own more than 9.99% of the Company’s outstanding common shares immediately after exercise, which percentage may be increased or decreased to any other percentage specified not in excess of 9.99% at the holder's election upon 61 days'  notice to the Company subject to the terms of the Exchange Warrants.

10

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

Additional Paid-in Capital

The additional paid-in capital balances were as follows:

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Opening balance

$

29,114

 

$

20,090

$

24,437

 

$

15,711

Share-based compensation expense

2,872

 

2,380

7,657

 

6,905

Exercise of stock options

(28)

 

(29)

(136)

 

(175)

Closing balance

$

31,958

 

$

22,441

$

31,958

 

$

22,441

8     Share Based Compensation

Under the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) and the Company’s Stock Option Plan (the “2011 Plan”), unless otherwise decided by the Board of Directors, options vest and are exercisable as follows: 25% vest and are exercisable on the one year anniversary of the grant date and one thirty-sixth (1/36th) of the remaining options vest and are exercisable each month thereafter, such that options are vested in full on four-year anniversary of the grant date.

On January 1, 2023 and on January 1, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,371,440 and 1,195,902 common shares, respectively. Further, on July 5, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,000,000 common shares. In addition, 125,323 options have been forfeited under the 2011 Plan since the adoption of the 2019 Plan and have become available for issuance under the 2019 Plan. As of September 30, 2023, 561,000 of previously issued options had been cancelled under the 2019 Plan and were available for future grants.  As of September 30, 2023, there were 8,182,946 common shares available for issuance under the 2019 Plan, of which 1,644,623 common shares were available for future grants.

On November 10, 2021, the Company established a 2021 Inducement Plan (the “Inducement Plan”) through the granting of awards. This 2021 Inducement Plan is intended to help the Company provide an inducement material for certain individuals to enter into employment with the Company, incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which employees may benefit from increases in value of the common shares. As of September 30, 2023, there were 1,000,000 shares available for issuance under the 2021 Inducement Plan, of which 497,000 shares were available for future grants.

On July 15, 2022, the Company offered an ESPP, in which participation is available to substantially all of our employees in the United States and Canada who meet certain service eligibility requirements. On January 1, 2023 the number of common shares reserved for issuance under the ESPP increased by 342,860 shares. As of September 30, 2023, the Company has 1,463,936 common shares available for issuance under the ESPP. As of September 30, 2023, the Company has issued 142,006 shares of common stock pursuant to the ESPP.

11

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

The total outstanding and exercisable options from the 2011 Plan, 2019 Plan and Inducement Plan as of September 30 were as follows:

2023

Weighted

Number

average

of shares

exercise

    

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

 

    

1,802,672

    

1,802,672

    

$

2.05

Outstanding at beginning of year - 2019 Plan

5,314,312

5,314,312

8.35

Outstanding at beginning of year - Inducement Plan

503,000

503,000

6.41

Granted - 2019 Plan

1,867,400

1,867,400

3.62

Exercised - 2019 Plan

(7,000)

(7,000)

3.74

Exercised - 2011 Plan

(105,779)

(105,779)

1.52

Forfeited - 2019 Plan

(87,861)

(87,861)

6.28

Expired - 2019 Plan

(58,617)

(58,617)

11.52

Expired - 2011 Plan

(343)

(343)

0.92

Cancelled - 2019 Plan

(561,000)

(561,000)

21.73

Outstanding at end of period

 

6,467,234

503,000

1,696,550

8,666,784

$

5.13

Outstanding at end of period - Weighted average exercise price

$

5.83

$

6.41

$

2.08

Exercisable at end of period

2,972,614

190,396

1,696,550

4,859,560

$

5.25

Exercisable at end of period - Weighted average exercise price

 

$

6.98

$

6.42

$

2.08

2022

Weighted

Number

average

of shares

exercise

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

    

1,995,971

1,995,971

$

2.07

Outstanding at beginning of year - 2019 Plan

 

3,759,834

3,759,834

9.51

Granted - 2019 Plan

1,748,700

1,748,700

5.78

Granted - Inducement Plan

523,000

523,000

6.37

Exercised - 2019 Plan

(15,089)

(15,089)

3.92

Exercised - 2011 Plan

(114,225)

(114,225)

1.38

Forfeited - 2019 Plan

(17,950)

(17,950)

14.31

Forfeited - 2011 Plan

(19,387)

(19,387)

9.42

Expired - 2011 Plan

(1,121)

(1,121)

0.96

Outstanding at end of period

5,475,495

523,000

1,861,238

7,859,733

$

6.70

Outstanding at end of period - Weighted average exercise price

$

8.32

$

6.37

$

2.04

Exercisable at end of period

2,219,125

1,831,482

4,050,607

$

6.28

Exercisable at end of period - Weighted average exercise price

$

9.79

$

2.01

The weighted average remaining contractual life was 7.5 and 7.8 years for outstanding options as of September 30, 2023 and 2022, respectively. The weighted average remaining contractual life was 6.4 and 6.7 years for vested options, as of September 30, 2023 and 2022, respectively.

There was $13.2 million and $18.6 million of total unrecognized compensation cost related to non-vested share options as of September 30, 2023 and 2022, respectively. The share options are expected to be recognized over a remaining weighted average vesting period of 2.4 years and 2.5 years as of September 30, 2023 and 2022, respectively. For the three and nine months ended September 30, 2023, there were 561,000 shares cancelled under the 2019 plan, which resulted in additional share-based compensation expense of $0.6 million.  

12

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

Options granted are valued using the Black-Scholes option pricing model. Amortization of the fair value of the options over vesting years has been expensed and credited to additional paid-in capital in shareholders’ equity.

The non-vested options as of September 30 were as follows:

2023

Number

Weighted

of options

average

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

    

 

2,126

2,126

 

$

6.64

Non-vested share options at beginning of year - 2019 Plan

2,923,763

2,923,763

 

5.30

Non-vested share options at beginning of year - Inducement Plan

503,000

503,000

4.84

Granted - 2019 Plan

 

1,867,400

1,867,400

2.87

Vested, outstanding 2011 Plan

(2,126)

(2,126)

 

6.64

Vested, outstanding 2019 Plan

(1,231,712)

(1,231,712)

6.09

Vested, outstanding Inducement Plan

(190,396)

(190,396)

4.85

Forfeited - 2019 Plan

(64,831)

(64,831)

4.08

Non-vested share options at end of period

 

3,494,620

312,604

3,807,224

 

$

3.83

Non-vested share options at end of period - Weighted average fair value

$

3.74

$

4.84

$

2022

Number

Weighted

of options

average

    

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

 

200,639

200,639

 

$

1.86

Non-vested share options at beginning of year - 2019 Plan

2,665,518

2,665,518

 

6.39

Granted - 2019 Plan

 

1,748,700

1,748,700

4.37

Granted - Inducement Plan

523,000

523,000

4.81

Vested, outstanding 2011 Plan

(170,883)

(170,883)

 

1.76

Forfeited - 2019 Plan

(8,731)

(8,731)

6.27

Vested, outstanding 2019 Plan

(1,149,117)

(1,149,117)

5.99

Non-vested share options at end of period

 

3,256,370

523,000

29,756

3,809,126

 

$

5.34

Non-vested share options at end of period - Weighted average fair value

$

5.45

$

4.81

$

2.44

The fair value of share-based payment transactions is measured using Black-Scholes valuation model. This model also requires assumptions, including expected option life, volatility, risk-free interest rate and dividend yield, which greatly affect the calculated values.

The fair value of options granted for the 2011 Plan, 2019 Plan and Inducement Plan were estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

 

2023

    

2022

 

Exercise price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Share price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Volatility

 

98

%  

93

%

 

98

%  

91

%

Risk-free interest rate

 

4.09

%  

2.94

%

 

3.92

%  

2.41

%

Expected life

 

6.08 years

 

5.75 years

 

6.00 years

 

6.03 years

Dividend

 

0

%  

0

%

 

0

%  

0

%

13

Table of Contents

Milestone Pharmaceuticals Inc.

Notes to Condensed Consolidated Financial Statements

For the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited)

(in thousands of US dollars, except where noted and for share and per share data)

Expected volatility is determined using comparable companies for which the information is publicly available. The risk-free interest rate is determined based on the U.S. sovereign rates benchmark in effect at the time of grant with a remaining term equal to the expected life of the option. Expected option life is determined based on the simplified method as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The simplified method is an average of the contractual term of the options and its ordinary vesting period. Dividend yield is based on the share option’s exercise price and expected annual dividend rate at the time of grant.

The Company recognized share-based compensation expense as follows:

Three months ended September 30, 

Nine months ended September 30, 

    

2023

    

2022

2023

    

2022

    

Administration

 

$

1,546

$

1,891

$

4,051

 

$

3,683

Research and development

 

900

349

2,526

 

2,302

Commercial activities

 

426

140

1,080

 

920

Total

 

$

2,872

$

2,380

$

7,657

 

$

6,905

9     Net Loss Per Share

Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and pre-funded warrants outstanding during the period.

For the three and nine months ended September 30, 2023 and 2022, the Company was in a net loss position. Dilutive net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and shares issuable upon exercise of pre-funded warrants outstanding during the period. In addition to the conversion feature on the 2029 Convertible Notes described above, which the Company reviewed and concluded would be anti-dilutive due to the facts surrounding the feature, the following potentially dilutive securities have also been excluded from the computation of diluted weighted average shares outstanding as of September 30, as they would be anti-dilutive:

    

2023

    

2022

Share options

 

8,666,784

 

7,859,733

Amounts above reflect the common share equivalents of the noted instruments.

10     Royalty Purchase Agreement

On March 27, 2023, we entered into a purchase and sale agreement, or the “Royalty Purchase Agreement”, with RTW and certain of its affiliates.

Pursuant to the Royalty Purchase Agreement, RTW agreed to purchase, following the U.S. Food and Drug Administration approval of etripamil (subject to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments, or the “Royalty Interest”,  on the annual net product sales of etripamil in the United States in an amount equal to: (i) 7%, or the “Initial Tier Royalty”, of annual net sales up to $500 million, (ii) 4% of annual net sales greater than $500 million and less than or equal to $800 million, and (iii) 1% of annual net sales greater than $800 million. If certain revenue thresholds for aggregate annual net sales are not met, the Initial Tier Royalty will increase to 9.5% beginning on January 1 of the following calendar year until a subsequent sales threshold is attained, at which time the Initial Tier Royalty would revert back to 7%.

Based on the Company’s assessment of the terms and conditions under the Royalty Purchase Agreement, there is no accounting recognition required in these interim financial statements.

14

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the unaudited interim condensed consolidated statements and the notes thereto included in this Quarterly Report on Form 10-Q and the audited annual consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission, or SEC, on March 29, 2023. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in “Risk Factors” and in other parts of this Quarterly Report on Form 10-Q.

Company Overview

We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our lead product candidate, etripamil, is a novel and potent calcium channel blocker that we designed as a rapid-onset nasal spray to be self-administered by patients. We are developing etripamil for the treatment of specific arrhythmias with a lead indication to treat paroxysmal supraventricular tachycardia, or PSVT, and an indication to treat atrial fibrillation with rapid ventricular rate, or AFib-RVR.

On October 23, 2023, we submitted the New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, seeking approval to sell and market etripamil for the treatment of paroxysmal supraventricular tachycardia, or PSVT. PSVT is a condition characterized by an abnormality in the electrical system of the heart causing patients to have unexpected, often severely symptomatic episodes of rapid heart rate.  Patients experiencing episodes of  supraventricular tachycardia, or SVT, often experience symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting and anxiety. Calcium channel blockers have long been approved for the treatment of PSVT as well as other cardiac conditions. Calcium channel blockers available in oral form are sometimes used prophylactically to attempt to control the frequency and duration of future episodes of SVT. For treatment of episodes of SVT, approved calcium channel blockers are administered intravenously under medical supervision, usually in the emergency department. We believe the combination of convenient nasal-spray delivery and rapid-onset of etripamil has the potential to shift the current treatment paradigm for episodes of SVT away from the burdensome and costly emergency department setting. If approved, we believe that etripamil will be the first self-administered therapy for the rapid termination of episodes of SVT wherever and whenever they occur.

On October 17, 2022, we announced positive and statistically significant topline efficacy and safety data from our Phase 3 RAPID clinical trial evaluating etripamil in patients with PSVT. These results from the RAPID trial were presented on November 7, 2022, as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions (Chicago, IL). These results were also published in the Lancet on July 8, 2023. RAPID, our multi-center, randomized, double-blind, placebo-controlled, event-driven Phase 3 trial, enrolled 706 patients across clinical sites in North America and Europe. Patients were randomized 1:1 using a self-administered regimen consisting of a first dose of study drug, and a repeat dose 10 minutes later if symptoms persisted. Self-administration was prompted by a patient’s symptoms and performed in the at-home setting without medical supervision. The RAPID trial achieved its primary endpoint with etripamil demonstrating a highly statistically significant and clinically meaningful difference in time to SVT conversion as compared to placebo. A Kaplan Meier analysis demonstrated a significantly greater proportion of patients who took etripamil converted to sinus rhythm within thirty minutes compared to patients that took placebo (64.3% vs. 31.2%; hazard ratio, or HR, 2.62; 95% CI 1.66, 4.15; p<0.001). By 90 minutes post-study drug administration, 80.6% of patients taking etripamil converted to sinus rhythm compared to 60.7% of patients taking placebo (HR = 1.93; 95% CI 1.349, 2.752; p<0.001). Statistically significant reductions in time to conversion in patients who took etripamil were evident early and persisted throughout the observation window of the trial compared to patients that took placebo. The median time-to-conversion for patients in the RAPID trial who self-administered etripamil was 17.2 minutes compared to 53.3 minutes for patients taking placebo. The safety and tolerability data from the RAPID trial supports the potential self-administration of etripamil, with findings consistent with those observed in prior trials. The most common randomized-treatment emergent adverse events, or RTEAEs, and adverse events, or AEs, occurred within 24 hours of etripamil administration and were related to the nasal local administration site. Overall, the majority of RTEAEs were reported as mild (68%) or moderate (31%). No serious adverse effects related to etripamil were reported.

15

The use of additional medical interventions and emergency department utilization were key secondary endpoints for both the RAPID and NODE-301 trials. In a pre-planned pooled analysis across both trials, patients who self-administered etripamil sought additional medical interventions 43% less frequently (15% vs. 25%; p=0.013) and had 39% fewer visits to the emergency department (14% vs. 22%; p=0.035) than patients in the placebo arm.

The NODE-301 trial was a placebo-controlled Phase 3 safety and efficacy trial. NODE-301 enrolled 431 patients across 65 sites in the United States and Canada. Although the trial did not meet its primary endpoint of time to conversion of SVT to sinus rhythm compared to placebo over the five-hour period following study drug administration in which patients wore a cardiac monitor, both prespecified and post hoc analyses at earlier time periods, namely at 30 minutes, showed significant treatment effects in favor of etripamil. For example, in a post hoc analysis of the NODE-301 data, 54% of patients taking etripamil vs. 35% of placebo patients converted to sinus rhythm within 30 minutes (HR 1.87, p=0.02). The safety and tolerability data from the NODE-301 trial support the potential self-administration of etripamil, with the most common RTEAEs and adverse events occurring within 24 hours of etripamil administration and relating to the nasal local administration site. Overall, the majority of RTEAEs were reported as mild (85%) to moderate (15%). No serious AEs related to etripamil were reported. After reviewing the data from NODE-301 with the FDA in July 2020, the FDA provided guidance that an analysis period shorter than five hours would be appropriate to measure the efficacy of etripamil. The FDA indicated that two trials, the RAPID and NODE-301 trials could potentially fulfill the efficacy requirement for an NDA for etripamil for the treatment of PSVT, both using time to conversion to sinus rhythm over the first 30 minutes with a target p-value of less than 0.05 as the primary endpoint. These results from the Phase 3 NODE-301 Part 1 and RAPID studies were featured in a poster session on May 9, 2023, at the ISPOR Annual Meeting in Boston, Massachusetts.

The NODE-303 trial was a Phase 3, multi-center, open-label safety trial, evaluating primarily the safety of etripamil when self-administered without medical supervision over multiple, separate SVT episodes. After consultation with FDA, we concluded that the test dose procedure was an unnecessary step for the self-administration of etripamil and it was not included in the requirements of the NODE-303 safety trial. The NODE-303 trial was initiated with an etripamil 70 mg single-dose regimen and the 70 mg optional repeat-dose regimen was introduced into the trial starting in the second half of 2021 following FDA acceptance of the protocol amendment. The trial was sized in order to provide safety data that we believed, when combined with data from remainder of the development program, would fulfill the safety and exposure dataset needed support an NDA filing. Following the results from the RAPID trial, initially obtained in October 2022, and subsequent discussions with the FDA which included the discussion of the total exposures to etripamil in the development program to date and guidance regarding the sufficiency of the safety dataset for submission of an NDA for PSVT, we closed the NODE-303 and RAPID extension studies, prepared our NDA package and submitted the package to the FDA on October 23, 2023.

AFib RVR Phase 2 Trial

On November 11, 2023, we announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with AFib-RVR compared to placebo. Safety and tolerability reported in the 56-patient safety population who received etripamil was generally consistent with that observed in our PSVT program discussed above.  We believe this data supports further development of self-administered etripamil for the treatment of AFib-RVR.

The randomized, placebo controlled Phase 2 ReVeRA trial enrolled 87 patients and dosed 56 patients aged 18 years and older with AFib who experienced a ventricular rate of 110 or more beats per minute (bpm) prior to receiving etripamil nasal spray. The trial was designed to assess the reduction in ventricular rate (primary endpoint), the time to achieve maximum reduction in ventricular rate, duration of effect, and patient satisfaction with treatment using the Treatment Satisfaction Questionnaire 9 (TSQM-9) patient reported outcome (PRO) tool (key secondary endpoints).

Data from ReVeRA trial showed that delivery of etripamil nasal spray significantly and rapidly reduced ventricular rate, consistent with the drug’s pharmacologic profile. Etripamil achieved the primary endpoint with high statistical significance with patients experiencing a ventricular rate reduction of 29.91 bpm (95% confidence interval: -40.31, -19.52; p<0.0001) in the etripamil arm compared to placebo. The maximum reduction in rate reported by a patient taking etripamil was 34.97 bpm. The median time to maximum reduction in ventricular rate was 13 minutes in patients taking etripamil.

16

ReVeRA Primary Endpoint – Maximum Reduction in Ventricular Rate from Baseline

Primary Endpoint: Maximum Reduction in VR from Baseline

Placebo NS,
N=251

Etripamil NS, 70 mg, N=241

Mean (95% CI), bpm

-5.06 (-7.44, -2.67)

-34.97 (-45.13, -24.87)

Difference in means (95% CI), bpm

--

-29.91 (-40.31, -19.52)

p-value2

--

<0.0001

1 Efficacy population (all randomized patients receiving study drug remaining in atrial fibrillation with adequately diagnostic ECG recordings for at least 60 min post drug)

2 From ANCOVA; calculations adjust for variance in baseline

Bpm = beats per minute, CI = confidence interval, NS = nasal spray, VR = ventricular rate

A greater number of patients taking etripamil achieved a ventricular rate of less than 100 bpm (58.3%) than those taking placebo (4%). Furthermore, 67% of patients taking etripamil achieved ventricular rate reductions of more than 20% and 96% of patients receiving etripamil achieved more than 10% in ventricular rate reductions in the first 60 minutes compared to 0% and 20% in patients taking placebo, respectively. Using the TSQM-9, compared to placebo, patients treated with etripamil demonstrated significant improvements in two satisfaction ratings: effectiveness (p<0.0001) and relief of symptoms (p=0.0002).

Treatment-emergent serious adverse events, or TESAEs, were rare, with two occurring in one  patient in the etripamil arm (3.7%) and four occurring in two patients in the placebo arm (6.9%). The TESAEs in the etripamil arm (transient severe bradycardia and syncope, assessed as due to hyper-vagotonia occurred in a patient with a history of vagal events, and fully resolved by placing the patient supine and was without sequelae. The most common (≥ 5%) adverse events were mild or moderate in intensity and included nasal discomfort, rhinorrhea, increased lacrimation, throat irritation and dizziness.

An estimated five million Americans suffer from AFib, a common arrhythmia marked by an irregular, disruptive and often rapid heartbeat. The Centers for Disease Control projects the prevalence of AFib will grow to an estimated 10 million patients by 2030. A subset of AFib patients experience episodes of abnormally high heart rate most often accompanied by palpitations, shortness of breath, dizziness, and weakness. While these episodes, known as AFib-RVR, may be treated by oral calcium channel blockers and/or beta blockers, patients frequently seek acute care in the emergency department to resolve symptoms. In 2016, nearly 800,000 patients were admitted to the emergency department due to AFib symptoms where treatment includes medically supervised intravenous administration of calcium channel blockers or beta blockers, or electrical cardioversion. ​

Planned Clinical Development for AFib-RVR

In June 2023, we met with the FDA for a pre-IND meeting. In this meeting, we received guidance from the FDA on a potential development path for etripamil in AFib-RVR. The FDA agreed that to gain a labelled indication via supplemental NDA (sNDA), a Phase 3,  randomized, placebo controlled, double blind clinical trial using a dosing regimen with self-administration of etripamil in an at-home setting could be acceptable with the support of the already existing safety database from our PSVT trials. The primary endpoint can be the reduction of ventricular rate, and the primary analysis would be on the intent to treat (ITT) population. In addition, the study would have to show statistical significance (p<0.05) on the key secondary endpoint of symptom relief as a patient benefit, also in the ITT population. The secondary endpoint could use a patient-reported outcomes measure (PRO) and the application of a 7-point anchored scale was discussed with the FDA. Based on our discussion, we believe a 1-unit improvement in the target population (that is, those patients treating an ECG-confirmed episode of AFib-RVR) could satisfy the clinical benefit requirement.

17

In the first quarter of 2024, we plan to propose to the FDA a Phase 3 clinical study for AFib-RVR conducted in the at-home setting consisting of patients with a history of symptomatic episodes and using a repeat-dose regimen of 70mg per dose similar to what was studied in the RAPID trial in patients with PSVT. Our target population would be patients with verified AFib-RVR, and the ITT population would be all patients self-administering the study drug for perceived AFib-RVR. The primary endpoint being considered is the mean change from baseline ventricular rate to nadir ventricular rate for patients treated with etripamil vs placebo, as was studied in the ReVeRA trial. Our key secondary endpoint would be based on a PRO acceptable to the FDA and the same or similar to ones we have used in our PSVT and AFib-RVR programs. We estimate that the study size would be approximately 150-200 unique patients treating an episode. This study may begin mid-2024 and have an approximate two-year duration to report top-line data.

Operations Overview

Since the initial commencement of our operations, we have devoted substantially all of our resources to performing research and development activities in support of our product development efforts, hiring personnel, raising capital to support and expand such activities, providing general and administrative support for these operations and, more recently, preparing for commercialization. We operate our business using a significant outsourcing model. As such, our team is composed of a relatively smaller core of employees who direct a significantly larger number of team members who are outsourced in the forms of vendors and consultants to enable execution of our operational plans. We do not currently have any products approved for sale, and we continue to incur significant research and development and general administrative expenses related to our operations.

Since inception, we have incurred significant operating losses. For the three months ended September 30, 2023 and 2022, we recorded net losses of $15.1 million and $14.6 million, respectively. For the nine months ended September 30, 2023 and 2022, we recorded net losses of $46.1 million and $45.2 million, respectively. As of September 30, 2023, we had an accumulated deficit of $312.4 million. We expect to continue to incur significant losses for the foreseeable future. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the necessary development activities required for obtaining regulatory approval and preparing for potential commercialization of our product candidates. We had $9.9 million of cash and cash equivalents and $65.9 million of short-term investments at September 30, 2023.

We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical trials and expenditures on other research and development activities. We expect our expenses will increase over time as we:

continue our ongoing and planned development of etripamil, including our Phase 3 and potentially future Phase 4 clinical trials of etripamil for the treatment of PSVT and future Phase 3 clinical trials of etripamil for the treatment of AFib-RVR;

seek marketing approvals for etripamil for the treatment of PSVT, AFib-RVR and other cardiovascular indications;

establish a sales, marketing, manufacturing and distribution capability, either directly or indirectly through third parties, to commercialize etripamil or any future product candidate for which we may obtain marketing approval;

build a portfolio of product candidates through development, or the acquisition or in-license of drugs, product candidates or technologies;

initiate preclinical studies and clinical trials for etripamil for any additional indications we may pursue, including the clinical trials for the treatment of atrial fibrillation and rapid ventricular rate as well as other areas of unmet medical need, and for any additional product candidates that we may pursue in the future;

maintain, protect and expand our intellectual property portfolio;

18

hire additional clinical, regulatory and scientific personnel;

add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and

incur additional legal, accounting, insurance and other expenses associated with operating as a public company.

The Macroeconomic Climate

The recent trends towards rising inflation may also materially adversely affect our business and corresponding financial position and cash flows. Inflationary factors, interest rates and overhead costs may adversely affect our operating results. Rising interest and inflation rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future., the Russia-Ukraine war, unrest and/or further escalation in Israel and Gaza, recent banking instabilities and other US geopolitical issues affecting other territories and employee availability and wage increases, and economic markets all of which may result in additional stress on our working capital resources.

Components of Results of Operations

Revenues

We have not generated any revenues from product sales to date and we do not expect to generate revenues from product sales in the near future. We recorded no revenue for the three months ended September 30, 2023 and $1.0 million in revenue during the nine months ended September 30, 2023. This revenue is due to a milestone reached as a result of the successful initiation of a Phase 1 Clinical Trial of the product by or on behalf of Ji Xing for the treatment of PSVT in the Territory. We recorded $1.5 million in revenue for the three and nine months ended September 30, 2022. This revenue was related to a milestone reached as a result of the first patient dosed in a Phase 3 Clinical Trial for the treatment of PSVT in the Territory.

Research and Development Expenses

Research and development expenses consist primarily of salaries and fees paid to external service providers and also include personnel costs, including share-based compensation expense and other related compensation expenses. We expense research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers.

To date, substantially all of our research and development expenses have been related to the preclinical and clinical development of etripamil. As we advance etripamil or other product candidates for other indications, we expect to allocate our direct external research and development costs across each of the indications or product candidates. Further, we expect our research and development costs to increase for the development of etripamil in atrial fibrillation with rapid ventricular rate, and we expect our research and development expenses related to the development of etripamil for PSVT decrease as a percentage of our total research and development expenses.

The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming and is subject to uncertainties and delays. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if at all.

We recognize the benefit of Canadian research and development tax credits as a reduction of research and development costs for fully refundable investment tax credits. General and administrative expenses include personnel and related compensation costs, expenses for outside professional services, lease expense, insurance expense and other general

19

administrative expenses. Personnel costs consist of salaries, bonuses, benefits, related payroll taxes and share-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees.

We expect to continue to incur expenses as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and those of any national securities exchange on which our securities are traded, additional insurance expenses, investor relations activities, and other administrative and professional services.

Commercial Expenses

Commercial expenses consist primarily of personnel and related compensation costs, market and health economic research, and market development activities for PSVT and, to a lesser extent, AFib-RVR. The focus of these expenses is three-fold: first, we want to leverage rigorous primary and secondary research to fully understand our target disease states from the perspective of the patient, healthcare provider, and payer; second, we want to understand and document the burden of disease posed by PSVT and AFib-RVR from an epidemiology, healthcare resource use, and cost perspective; and third, we want to engage our target patient, physician, and payer stakeholders with evidence-based and compliant educational materials that serve to increase the awareness and understanding of the impact of PSVT and AFib-RVR on patients and the overall healthcare system.

We anticipate our commercial expenses will increase as we invest in the infrastructure, personnel, and operational expenses required to launch our first product in the United States, if the FDA approves the NDA.

Interest Income

Interest income primarily consists of interest income from our cash equivalents and short-term investments.

Interest Expense

Interest expense primarily consists of contractual debt interest expense and the amortization of debt costs.

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2023 and 2022

The following table summarizes our results of operations and changes:

Three months ended September 30, 

(in thousands)

    

2023

    

2022

$ Change

    

% Change

Revenue

$

$

1,500

(1,500)

0.0%

Operating expenses

Research and development, net of tax credits

$

6,721

$

9,826

$

(3,105)

 

(31.6)%

General and administrative

 

4,227

 

4,034

 

193

 

4.8%

Commercial

 

4,412

 

2,670

1,742

 

65.2%

Total operating expenses

 

15,360

 

16,530

 

(1,170)

 

(7.1)%

Loss from operations

 

(15,360)

 

(15,030)

 

(330)

 

2.2%

Interest income

 

1,120

 

474

 

646

 

136.3%

Interest expense

(841)

(841)

100.0%

Net loss

$

(15,081)

$

(14,556)

$

(525)

 

3.6%

20

Nine months ended September 30, 

(in thousands)

    

2023

    

2022

$ Change

    

% Change

Revenue

$

1,000

$

1,500

$

(500)

 

100.0%

Operating expenses

Research and development, net of tax credits

25,600

29,251

(3,651)

 

(12.5)%

General and administrative

 

12,561

 

11,595

 

966

 

8.3%

Commercial

 

10,137

 

6,537

 

3,600

 

55.1%

Total operating expenses

 

48,298

 

47,383

 

915

 

1.9%

Loss from operations

 

(47,298)

 

(45,883)

 

(1,415)

 

3.1%

Interest income

 

2,921

672

 

2,249

 

334.7%

Interest expense

(1,697)

(1,697)

100.0%

Net loss

(46,074)

 

(45,211)

(863)

 

1.9%

Revenue

We recorded no revenue for the three months ended September 30, 2023 and $1.0 million in revenue during the nine months ended September 30, 2023. This revenue was the result of having reached a milestone pursuant to our License and Collaboration Agreement, dated May 15, 2021, with Ji Xing Pharmaceuticals Limited (such party “Ji Xing” and , such agreement, the “Ji Xing License Agreement”) due upon the successful initiation of a Phase 1 Clinical Trial of a pharmaceutical product that uses a device to deliver etripamil by nasal spray by or on behalf of Ji Xing for the treatment of PSVT in the People’s Republic of China (the “Territory”), including mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan.

We recorded $1.5 million in revenue for the three and nine months ended September 30, 2022. This revenue was related to a milestone reached as a result of the first patient dosed in a Phase 3 Clinical Trial for the treatment of PSVT in the Territory pursuant to the Ji Xing License Agreement.

Research and Development Expenses

The following table shows our research and development expenses by type of activity for the three and nine months ended September 30, 2023 and 2022, respectively.

Three months ended September 30, 

Nine months ended September 30, 

(in thousands)

    

2023

    

2022

$ Change

    

% Change

    

2023

    

2022

$ Change

    

% Change

Clinical

$

3,157

$

7,886

$

(4,729)

 

(60.0)%

$

16,526

$

23,704

$

(7,178)

 

(30.3)%

Drug manufacturing and formulation

 

2,111

 

1,389

 

722

 

52.0%

 

5,535

 

3,564

 

1,971

 

55.3%

Regulatory and other costs

 

1,539

 

688

 

851

 

123.7%

 

3,777

 

2,303

 

1,474

 

64.0%

Less: R&D tax credits

 

(86)

 

(137)

 

51

 

(37.2)%

 

(238)

 

(320)

 

82

 

(25.6)%

Total R&D expenses

$

6,721

$

9,826

$

(3,105)

 

(31.6)%

$

25,600

$

29,251

$

(3,651)

 

(12.5)%

Research and development expenses decreased by $3.1 million, or 31.6%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease was primarily due to lower clinical expenses. This decrease in clinical expenses was driven by lower clinical development costs and clinical personnel-related costs as a result of the completion of phase 3 studies. The decrease in clinical costs was partially offset by an increase in drug manufacturing consulting costs, drug manufacturing personnel costs and regulatory consulting costs.

Research and development expenses decreased by $3.7 million, or 12.5%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The decrease was primarily due to lower clinical expenses driven by lower clinical development costs and clinical personnel-related costs as a result of the completion of phase 3 studies.

21

The decrease in clinical costs was partially offset by an increase in drug manufacturing consulting costs, drug manufacturing personnel costs, regulatory personnel costs and regulatory consulting costs.

We recognize the benefit of Canadian research and development tax credits as a reduction of research and development costs for fully refundable investment tax credits.

General and Administrative

General and administrative expenses remained consistent for the three months ended September 30, 2023 and the three months ended September 30, 2022.

General and administrative expenses increased by $1.0 million, or 8.3%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The primary contributor was an increase in personnel-related costs and consulting fees for general and administrative expenses.

Commercial

Commercial expenses increased by $1.7 million, or 65.2%, for the three months ended September 30, 2023, compared to the same period in 2022. This increase is a result of additional personnel and professional costs required to expand capabilities and operations in anticipation of potential commercialization.

Commercial expenses increased by $3.6 million, or 55.1%, for the nine months ended September 30, 2023, compared to the same period in 2022. This increase is a result of  additional personnel and professional costs required to expand capabilities and operations in anticipation of potential commercialization.

We anticipate our commercial expenses will increase as we invest in the infrastructure, personnel and operational expenses required to launch our first product in the United States, if the FDA approves the NDA.

Interest Income

Interest income was $1.1 million and $0.5 million for the three months ended September 30, 2023 and 2022, respectively. Interest income was $2.9 million and $0.7 million for the nine-month periods ended September 30, 2023 and 2022, respectively. The increase in interest income was due to higher interest rates earned on investments in 2023 when compared to 2022.

Interest Expense

Interest expense was $0.8 million for the three months ended September 30, 2023 compared to no interest expense for the three months ended September 30, 2022. Interest expense was $1.7 million for the nine months ended September 30, 2023 compared to no interest expense for the nine months ended September 30, 2022. The increase in interest expense was due to the issuance of the 2029 Convertible Notes in the first quarter of 2023.  

Liquidity and Capital Resources

Sources of Liquidity

We have incurred operating losses and experienced negative operating cash flows since our inception, and we anticipate continuing to incur losses for at least the next several years. As of September 30, 2023, we had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million.

On March 27, 2023, we entered into a purchase and sale agreement, or the Royalty Purchase Agreement, and a note purchase agreement, or the Note Purchase Agreement, with RTW Investments, LP and certain of its affiliates, or collectively, RTW.

22

On March 29, 2023, the Company closed the transaction contemplated by the Note Purchase Agreement and issued and sold the $50 million principal amount of 6.0% Convertible Senior Notes due 2029, or the 2029 Convertible Notes, to the holders in a private placement transaction.

The 2029 Convertible Notes are senior secured obligations and are guaranteed on a senior secured basis by our wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc. Interest, at the annual rate of 6.0%, is payable quarterly in cash or, at our option, payable in kind for the first three years. The maturity date for the 2029 Convertible Notes will be March 31, 2029. The obligations under the 2029 Convertible Notes are secured by substantially all of our and our subsidiary guarantor’s assets.

Each $1,000 of principal of the 2029 Convertible Notes (including any interest added thereto as payment in kind) is convertible into 191.0548 shares of our common shares, equivalent to an initial conversion price of approximately $5.23 per share, subject to customary anti-dilution and other adjustments. Subject to specified conditions, on or after March 27, 2027, the 2029 Convertible Notes are redeemable by us subject to certain conditions, at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

On July 29, 2020, we entered into an Open Market Sale AgreementSM, or the “Sales Agreement”, with Jefferies LLC with respect to an at-the-market offering program, or the “ATM Program”, under which the Company may issue and sell its common shares having an aggregate offering price of up to $50 million through Jefferies as its sales agent or principal. The common shares to be sold under the Sales Agreement, are offered and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-239318), which was declared effective by the SEC on July 6, 2020. During 2022, we issued 361,236 shares under the Sales Agreement, resulting in net proceeds of $2.6 million (net of issuance costs of $0.1 million).

We expect that our operating plan, existing cash and cash equivalents and short-term investments to be sufficient to fund our operations for at least the next 12 months from the date of issuance of this 10-Q for the quarter ending September 30, 2023 and that there are no events or conditions that may cast substantial doubt on our ability to continue as a going concern for at least the next 12 months from the date of this filing.

Contingent future source of funding

Pursuant to the Royalty Purchase Agreement, RTW agreed to purchase, following U.S. Food and Drug Administration (FDA) approval of etripamil (subject to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments, or “royalty interest”, on the annual net product sales of etripamil in the United States. This represents a contingent future source of funding, in order for the Company to receive the $75 million dollars, the closing conditions specified in the Royalty Purchase Agreement, which includes the Company receiving marketing approval from the FDA on or prior to September 30, 2025, must be met.

Funding Requirements

We use our cash primarily to fund research and development expenditures. We expect our research and development expenses to increase as we continue the development of etripamil and prepare to pursue regulatory approval. We expect to incur an increase in general and administrative expenses, and an increase in expenses related to commercial activities in 2023 as we focus our efforts on the clinical pathway and potential commercialization of etripamil. We expect to incur increasing operating losses for the foreseeable future as we continue the clinical development of our product candidate. At this time, due to the inherently unpredictable nature of clinical development, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval, and commercialize etripamil or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations.

In addition, we have exclusive development and commercialization rights for etripamil for all indications that we may pursue and as such have the potential to license development and or commercialization rights for etripamil to a potential partner in regions outside of Greater China. We plan to establish commercialization and marketing capabilities using a

23

direct sales force to commercialize etripamil in the United States. Outside of the United States, we are considering commercialization strategies that may include collaborations with other companies.

For other new product candidates, our efforts are focused on licensing development and/or commercialization rights from potential partners.  In the case of either in-licensing or out-licensing, we cannot forecast when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development and commercialization plans and capital requirements.

The timing and amount of our operating expenditures will depend largely on:

the timing, progress and results of our ongoing and planned clinical trials and other development activities of etripamil in PSVT, AFib-RVR and in other cardiovascular indications;

the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of etripamil for additional indications or any future product candidates that we may pursue;

our ability to establish additional collaborations on favorable terms, if at all;

the ability of vendors and third-party service providers to accurately forecast expenses and deliver on expectations;

the costs, timing and outcome of regulatory review of etripamil and any future product candidates;

the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for etripamil and any future product candidates for which we receive marketing approval;

the revenue, if any, received from commercial sales of etripamil and any future product candidates for which we receive marketing approval;

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and

the extent to which we acquire or in-license other product candidates and technologies.

Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our shareholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition and results of operations.

24

Cash Flows

The following table summarizes our cash flows for the periods indicated:

Nine months ended September 30, 

(in thousands)

2023

    

2022

$ Change

 % Change

Net cash (used in) provided by:

Operating activities

$

(36,628)

$

(39,607)

2,979

 

(7.5)%

Investing activities

(8,920)

(40,109)

31,189

 

(77.8)%

Financing activities

47,791

2,861

44,930

 

1570.4%

Net increase (decrease) in cash and cash equivalents during the period

$

2,243

 

$

(76,855)

79,098

 

Operating Activities

Net cash used in operating activities during the nine months ended September 30, 2023 was $36.6 million, which consisted primarily of a net loss of $46.0 million. The net loss was partially offset by a net cash increase of $0.1 million related to the change in assets and liabilities, non-cash charges of $7.7 million related to share-based compensation and non-cash interest charges of $1.5 million related to the convertible note.

Net cash used in operating activities during the nine months ended September 30, 2022 was $39.6 million, which consisted of a net loss of $45.2 million and a net decrease of $1.4 million in our operating assets and liabilities due to increases in prepaid expenses and other receivables and a decrease in accounts payable offset by non cash charges of $7.0 million related to share based compensation and depreciation expenses.

Investing Activities

In the nine months ended September 30, 2023 we acquired $95.8 million of short-term investments and we redeemed $87.0 million in short-term investments.  In the nine months ended September 30, 2022 we acquired $63.0 million of short-term investments while we divested of $23.0 million.

Financing Activities

In the nine months ended September 30, 2023, our financing activities provided cash proceeds of $47.8 million. These proceeds were primarily a result of the $50 million received from the issuance of convertible notes under the Note Purchase Agreement, which was partially offset by $2.8 million in debt costs, and $0.6 million in cash proceeds from the exercise of share options and issuance of common shares under the employee stock purchase plan. In the nine months ended September 30, 2022, our financing activities provided a de minimis amount of proceeds from the exercise of share options. In August 2022, the Company issued and sold 361,236 common shares under the Sales Agreement for proceeds of $2.6 million (net of issuance costs of $0.1 million).

We have not entered into off-balance sheet arrangements.

Contractual Obligations

With the exception of the 2029 Convertible Notes outlined above, during the nine months ended September 30, 2023, there were no material changes to our contractual obligations and commitments described under Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K, filed with the SEC on March 29, 2023.

Critical Accounting Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited interim consolidated financial statements as of September 30, 2023, which have been prepared in accordance with United

25

States generally accepted accounting principles, or U.S. GAAP and on a basis consistent with those accounting principles followed by us. The preparation of these consolidated financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to:

Estimates of the percentage of work completed of the total work over the life of the individual trial in accordance with agreements established with CROs, CMOs and clinical trial sites which in turn impact the research & development expenses.
Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.

Accordingly, actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

a) Research & Development Expenses — Accruals

Research and development costs are charged against income in the period of expenditure. Our research and development costs consist primarily of salaries and fees paid to CROs and to CMOs.

Clinical trial expenses include direct costs associated with CROs, direct CMO costs for the formulation and packaging of clinical trial material, as well as investigator and patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs and CMOs are generally payable on a time-and-materials basis, or when milestones are achieved. The invoicing from clinical trial sites can lag several months. We record expenses for our clinical trial activities performed by third parties based upon estimates of the percentage of work completed of the total work over the life of the individual trial in accordance with agreements established with CROs and clinical trial sites. We determine the estimates through discussions with internal clinical personnel, CROs and CMOs as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services based on facts and circumstances known to us as of each consolidated balance sheet date. The actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan. If the actual timing of the performance of services of the level of effort varies from the estimate, we will adjust the accrual accordingly. Adjustments to prior period estimates have not been material. We recognize the benefit of Canadian research and development tax credits as a reduction of research and development costs for fully refundable investment tax credits and as a reduction of income taxes for investment tax credits that can only be claimed against income taxes payable when there is reasonable assurance that the claim will be recovered.

b) Share-Based Compensation

We recognize compensation costs related to share options granted to employees, consultants and directors based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. This Black-Scholes option pricing model uses various inputs to measure fair value, including estimated fair value of our underlying common shares at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of our common shares. The estimated volatility creates a critical estimate because we have not been a public company long enough to demonstrate our own historical volatility. The grant date fair value of the share-based awards is recognized on a straight-line basis over the requisite service periods, which are generally the vesting period of the respective awards. Forfeitures are accounted for as they occur.

26

Recent Accounting Pronouncements

Refer to Note 2, “Summary of Significant Accounting Policies,” for a discussion of recent accounting pronouncements and to the notes to our audited consolidated financial statements as of December 31, 2022 appearing in our Annual Report on Form 10-K, filed with the SEC on March 29, 2023.

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly increasing risk. We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks. We had cash, cash equivalents and short-term investments of $75.7 million as of September 30, 2023, which consist primarily of bank deposits and guaranteed investment certificates. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we do not believe an immediate 10% increase or decrease in interest rates would have a material effect on the fair market value of our portfolio, and accordingly we do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.

We undertake certain transactions in Canadian dollars and as such are subject to risk due to fluctuations in exchange rates. Canadian dollar denominated payables are paid at the converted rate as due. We do not use derivative instruments to hedge exposure to foreign exchange rate risk due to the low volume of transactions denominated in foreign currencies. On September 30, 2023 our net monetary exposure denominated in Canadian dollars was $0.6 million.

Our operating results and financial position are reported in U.S. dollars in our consolidated financial statements. The fluctuation of the Canadian dollar in relation to the U.S. dollar might, consequently, have an impact upon our loss and may also affect the value of our assets and the amount of shareholders’ equity.

We do not have a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our consolidated financial results.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the “Exchange Act”, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. Based upon the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.

27

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

Aside from the risk factor listed below, there have been no material changes from the risk factors previously disclosed in Part I, Item 1A. in our Annual Report on Form 10-K, filed with the SEC and under Milestone’s SEDAR profile at www.sedarplus.com on March 29, 2023.

Healthcare legislative reform measures may have a negative impact on our business and results of operations.

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010 the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as PPACA, was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the United States. There have been executive, judicial and Congressional challenges to certain aspects of the PPACA. For example, the Tax Cuts and Jobs Act of 2017, or the “Tax Act”, was enacted, which included a provision that repealed, effective January 1, 2019, the tax based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA mandated “Cadillac” tax on high cost employer sponsored health coverage and medical

28

device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any additional healthcare reform measures of the Biden administration will impact the PPACA and our business.

Further, in the United States there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, Presidential executive order and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. For example, in July 2021, the Biden administration released an executive order, “Promoting Competition in the American Economy,” with multiple provisions aimed at prescription drugs. In response to Biden’s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively, starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration’s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future. We expect that additional U.S. healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for etripamil or any future product candidates or additional pricing pressures.

In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act and the Consolidated Appropriations Act of 2023, will remain in effect through 2032, unless additional Congressional action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other

29

things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

We cannot predict the likelihood, nature or extent of health reform initiatives that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, etripamil or any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable

Item 3. Defaults Upon Senior Securities.

Not applicable

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

Not applicable

30

Item 6. Exhibits.

Exhibit
Number

    

Description

3.1

Amended Articles of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).

3.2

Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on May 15, 2019).

4.1

Form of Exchange Warrant (incorporated herein by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K (File No. 001-38899), filed with the SEC on March 27, 2023).

10.1

First Amendment to Note Purchase Agreement, dated as of August 4, 2023.

10.2

Non-Employee Director Compensation Policy, as amended.

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL.

*        Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the “Exchange Act (whether made before or after the date of the Form 10-Q)”, irrespective of any general incorporation language contained in such filing.

31

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MILESTONE PHARMACEUTICALS INC.

Date: November 13, 2023

By:

/s/ Joseph Oliveto

Joseph Oliveto

President and Chief Executive Officer
(Principal Executive Officer)

Date: November 13, 2023

By:

/s/ Amit Hasija

Amit Hasija

Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

32

EX-10.1 2 mist-20230930xex10d1.htm EX-10.1

Exhibit 10.1

Execution Version

FIRST AMENDMENT TO

NOTE PURCHASE AGREEMENT

This FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of August 4, 2023 (“Amendment”), is made by and among Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), the Purchasers (defined below), RTW Investments, LP, as agent for the Purchasers (in such capacity, the “Principal Purchaser”) and acknowledged and agreed by Acquiom Agency Services LLC, as collateral agent for the Purchasers (in such capacity, the “Collateral Agent”). Capitalized terms used herein, but not otherwise defined herein shall have the respective meanings set forth in the Note Purchase Agreement (defined below).

WITNESSETH:

WHEREAS, the Company entered into the Note Purchase Agreement, dated as of March 27, 2023 (the “Note Purchase Agreement”), with the purchasers from time to time party thereto (each, a “Purchaser”, and collectively, the “Purchasers”), the Principal Purchaser, and the Collateral Agent, pursuant to which the Company has issued $50,000,000 aggregate principal amount of its 6.0% Convertible Senior Secured Notes due March 31, 2029 (each as amended, restated, supplemented or otherwise modified from time to time, the “Notes”); and

WHEREAS, in accordance with Section 13.6 of the Note Purchase Agreement, the Company, the Purchasers, and the Principal Purchaser have agreed that Section 7 of the Note Purchase Agreement be amended.

NOW, THEREFORE, in consideration of the covenants and agreements contained herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

SECTION 1. Amendments. Effective as of the Amendment Effective Date (as defined below):

(a) Section 1.1 is amended by adding the following term with the following meaning:

Grantor” means the Company and the Guarantors.

(b) Section 7.1 is amended by adding a Section 7.1(d) with language as follows:

(d) enter into any control agreement, blocked account, lockbox or similar arrangement with the applicable depository institution or intermediary, the applicable Grantor and any secured party (other than the Collateral Agent) with respect to any deposit accounts securities accounts and commodities accounts held or maintained in Canada (excluding any Excluded Account (as defined in the Guarantee and Collateral Agreement)), other than in connection with Indebtedness permitted under Section 7.1(b)(v) hereof, provided that such


Indebtedness will be subject to subject to customary first lien/second lien intercreditor arrangements.

(c) The requirement to deliver control agreements for any Closing Date Account held in Canada pursuant to paragraph 2 on Schedule C to the Note Purchase Agreement is hereby removed.

SECTION 2. Conditions to Amendment Effectiveness. The effectiveness of this Amendment is subject to satisfaction of the following conditions precedent (the date of such satisfaction being the “Amendment Effective Date”):

(a)(i) the Company shall have executed and delivered a counterpart of this Amendment to each Purchaser and the Principal Purchaser and (ii) each Purchaser and the Principal Purchaser shall have executed and delivered counterparts of this Amendment to the Company; and

(b) no Event of Default shall have occurred and be continuing before and immediately after giving effect to this Amendment.

SECTION 4. Representations and Warranties. The Company hereby represents and warrants to each Purchaser and the Principal Purchaser, on and as of the Amendment Effective Date, that:

(a)  The Company has all requisite corporate power and has taken all necessary corporate action required for the due authorization, execution, delivery and performance by the Company of this Amendment and the other Note Documents and the consummation of the transactions contemplated hereby and thereby. The execution, delivery and performance by the Company of this Amendment and the consummation by the Company of the transactions contemplated hereby, have been duly authorized by the Board of Directors and no further consent or authorization of the Company, the Board of Directors or its shareholders is required. This Amendment has been duly executed and delivered by the Company, and the other instruments referred to herein, including the Note Documents, to which it is a party and any Note Document to which it is a party will be duly executed and delivered by the Company, and each such instrument or Note Document constitutes or will constitute a legal, valid and binding obligation of the Company enforceable against it in accordance with its terms, except to the extent that enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

SECTION 5. Effects on the Note Purchase Agreement.

(a)  On and after the Amendment Effective Date, each reference in the Note Purchase Agreement or any Note Document to the Note Purchase Agreement shall mean and be a reference to the Note Purchase Agreement as amended by this Amendment, and each reference in the Note Purchase Agreement to “this Agreement,” “hereunder,” “hereof” or words of like import shall mean and be a reference to the Note Purchase Agreement as amended by this Amendment.


(b)  This Amendment does not constitute a novation or termination of the obligations under the Note Purchase Agreement; and except as specifically amended or otherwise modified hereby, all of the Note Documents shall continue to be in full force and effect and are hereby in all respects ratified and confirmed and no provision of the Note Purchase Agreement (including the definition of Final Availability Date therein) or the other Note Documents are amended in any way other than as expressly provided herein.

(c)  Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Purchasers, Principal Purchaser or the Company under any Note Document.

(d)  This Amendment shall constitute a Note Document for all purposes of the Note Purchase Agreement and the other Note Documents.

SECTION 6. Miscellaneous.

(a)Sections 13.2, 13.8, 13.9 of the Note Purchase Agreement are hereby incorporated herein by reference mutatis mutandis.

(b)The undersigned Purchasers, constituting all of the Purchasers, hereby direct the Collateral Agent to execute this Amendment.

[Remainder of page intentionally left blank; signature pages follow.]


IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Amendment as of the date first above written.

MILESTONE PHARMACEUTICALS INC.

By:

/s/Amit Hasija

Name:

Amit Hasija

Title:

Chief Executive Officer


This Amendment is hereby

acknowledged and agreed to as

of the date hereof by.

COLLATERAL AGENT:

Acquiom Agency Services LLC

By:

/s/Shon McCraw-Davis

Name:

Shon McCraw-Davis

Title:

Director


RTW INVESTMENTS, LP,

as the Principal Purchaser

By:

/s/ Roderick Wong, M.D.

Name:

Roderick Wong, M.D.

Title:

Managing Partner


This Amendment is hereby
accepted and agreed to as
of the date hereof.

RTW MASTER FUND, LTD.

By:

/s/ Darshan Patel

Name:

Darshan Patel

Title:

Director

RTW INNOVATION MASTER FUND, LTD.

By:

/s/ Darshan Patel

Name:

Darshan Patel

Title:

Director

RTW BIOTECH OPPORTUNITIES LTD (F/K/A RTW VENTURE FUND LIMITED)

By:

RTW Investments, LP, its Investment Manager

By:

/s/ Roderick Wong, M.D.

Name:

Roderick Wong, M.D.

Title:

Managing Partner


EX-10.2 3 mist-20230930xex10d2.htm EX-10.2

Exhibit 10.2

MILESTONE PHARMACEUTICALS INC.

AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

Each member of the Board of Directors (the “Board”) of Milestone Pharmaceuticals Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. This Policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments to be paid thereafter. All annual cash fees are vested upon payment.

1.

Annual Board Service Retainer:

a.

All Eligible Directors: $42,500

b.

Non-executive chairperson of the Board: $72,500 (inclusive of Annual Board Service Retainer)

2.

Annual Committee Member Service Retainer:

a.

Member of the Audit Committee: $10,000

b.

Member of the Compensation Committee: $7,500

c.

Member of the Nominating and Corporate Governance Committee: $5,000

d.

Member of the Clinical Affairs Committee: $6,000

3.

Annual Committee Chair Service Retainer (inclusive of Committee Member Service Retainer):

a.

Chairperson of the Audit Committee: $20,000

b.

Chairperson of the Compensation Committee: $15,000

c.

Chairperson of the Nominating and Corporate Governance Committee: $10,000

d.

Chairperson of the Clinical Affairs Committee: $12,000


The Company will also reimburse each of the Eligible Directors for his or her travel expenses incurred in connection with his or her attendance at Board and committee meetings. Such reimbursements shall be paid on the same date as the annual cash fees are paid.

Equity Compensation

The equity compensation set forth below will be granted under the Company’s 2019 Equity Incentive Plan (the “Plan”), subject to the approval of the Plan by the Company’s shareholders. All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock on the date of grant, and a term of 10 years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).

1.

Initial Grant: For each Eligible Director who is first elected or appointed to the Board following the effective date of this Policy, on the date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase a number of shares of the Company’s common stock equal to 42,000 shares of the Company’s common stock. The shares subject to each such stock option will vest monthly over a three-year period, subject to the Eligible Director’s Continuous Service (as defined in the Plan) on each vesting date.

2.

Annual Grant: On the date of each annual shareholder meeting of the Company held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such shareholder meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 25,000 shares of the Company’s common stock (the “Annual Grant”). The shares subject to the Annual Grant will vest in equal monthly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of Company’s next annual shareholder meeting, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

Approved: April 26, 2019

Effective: May 8, 2019

Amended: May 4, 2020

Amended: September 21, 2020

Amended and Restated: March 24, 2021

Amended and Restated: February 14, 2023

Amended and Restated: July 1, 2023


EX-31.1 4 mist-20230930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joseph Oliveto, certify that:

1.           I have reviewed this Quarterly Report on Form 10-Q of Milestone Pharmaceuticals Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2023

/s/ Joseph Oliveto

Joseph Oliveto

President and Chief Executive Officer

(Principal Executive Officer)


EX-31.2 5 mist-20230930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Amit Hasija, certify that:

1.           I have reviewed this Quarterly Report on Form 10-Q of Milestone Pharmaceuticals Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2023

/s/ Amit Hasija

Amit Hasija

Chief Financial Officer

(Principal Financial Officer and Principal Accounting

Officer)


EX-32.1 6 mist-20230930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Joseph Oliveto, Chief Executive Officer of Milestone Pharmaceuticals Inc. (the “Company”), and Amit Hasija, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1.            The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.            The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 13, 2023

    

/s/ Joseph Oliveto

/s/ Amit Hasija

Joseph Oliveto

Amit Hasija

Chief Executive Officer

Chief Financial Officer

(Principal Executive Officer)

(Principal Financial Officer and Principal Accounting Officer)


EX-101.SCH 7 mist-20230930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Loss link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Debt - Convertible Note (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Debt - Total amount of interest cost (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Shareholders' Equity - Authorized share capital (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Shareholders' Equity - Additional paid-in capital (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Share Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Share Based Compensation - Outstanding and exercisable options (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Share Based Compensation - Non-vested share options (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Share Based Compensation - Weighted average assumptions for the options granted (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Share Based Compensation - Recognized share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Royalty Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Share Based Compensation link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Royalty Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mist-20230930_cal.xml EX-101.CAL EX-101.DEF 9 mist-20230930_def.xml EX-101.DEF EX-101.LAB 10 mist-20230930_lab.xml EX-101.LAB EX-101.PRE 11 mist-20230930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2023
Nov. 13, 2023
Document and Entity Information    
Document Type 10-Q  
Document Period End Date Sep. 30, 2023  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 001-38899  
Entity Registrant Name Milestone Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code A8  
Entity Tax Identification Number 00-0000000  
Entity Address, Address Line One 1111 Dr. Frederik-Philips Boulevard  
Entity Address, Address Line Two Suite 420  
Entity Address, City or Town Montréal  
Entity Address, State or Province QC  
Entity Address, Country CA  
Entity Address, Postal Zip Code H4M 2X6  
City Area Code 514  
Local Phone Number 336-0444  
Title of 12(b) Security Common Shares  
Trading Symbol MIST  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   33,483,111
Entity Central Index Key 0001408443  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 9,879 $ 7,636
Short-term investments 65,867 56,949
Research and development tax credits receivable 569 331
Prepaid expenses 6,961 6,005
Other receivables 1,521 882
Total current assets 84,797 71,803
Operating lease assets 2,047 2,423
Property and equipment 272 257
Total assets 87,116 74,483
Current liabilities    
Accounts payable and accrued liabilities 7,584 5,644
Operating lease liabilities 530 495
Total current liabilities 8,114 6,139
Operating lease liabilities, net of current portion 1,583 1,996
Senior secured convertible notes 48,915  
Total liabilities 58,612 8,135
Shareholders' Equity    
Common shares, no par value, unlimited shares authorized 33,481,787 shares issued and outstanding as of September 30, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022 260,502 273,900
Pre-funded warrants - 9,577,257 issued and outstanding as of September 30, 2023 and 8,518,257 as of December 31, 2022 48,459 34,352
Additional paid-in capital 31,958 24,437
Accumulated deficit (312,415) (266,341)
Total shareholders' equity 28,504 66,348
Total liabilities and shareholders' equity $ 87,116 $ 74,483
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Condensed Consolidated Balance Sheets    
Common shares, par value (in dollars per share) $ 0 $ 0
Common shares, Shares authorized (in shares) Unlimited Unlimited
Common shares, Shares issued (in shares) 33,481,787 34,286,002
Common shares, Shares outstanding (in shares) 33,481,787 34,286,002
Warrants issued 9,577,257 8,518,257
Warrants outstanding 9,577,257 8,518,257
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Condensed Consolidated Statements of Loss        
Revenue $ 0 $ 1,500 $ 1,000 $ 1,500
Operating expenses        
Research and development, net of tax credits 6,721 9,826 25,600 29,251
General and administrative 4,227 4,034 12,561 11,595
Commercial 4,412 2,670 10,137 6,537
Loss from operations (15,360) (15,030) (47,298) (45,883)
Interest income 1,120 474 2,921 672
Interest expense (841)   (1,697)  
Net loss and comprehensive loss $ (15,081) $ (14,556) $ (46,074) $ (45,211)
Weighted average number of shares and pre-funded warrants outstanding, basic 42,973,160 42,491,787 42,920,620 42,339,123
Weighted average number of shares and pre-funded warrants outstanding, diluted 42,973,160 42,491,787 42,920,620 42,339,123
Net loss per share, basic $ (0.35) $ (0.34) $ (1.07) $ (1.07)
Net loss per share, diluted $ (0.35) $ (0.34) $ (1.07) $ (1.07)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Common Shares
Pre-funded warrants
Additional paid-in capital
Accumulated deficit
Total
Opening balance at Dec. 31, 2021 $ 251,901 $ 52,941 $ 15,711 $ (207,953) $ 112,600
Balance at the beginning of period (in shares) at Dec. 31, 2021 29,897,559 12,327,780      
Increase (Decrease) in Stockholders' Equity          
Net loss       (45,211) (45,211)
Exercise of stock options $ 392   (175)   217
Exercise of stock options (in shares) 129,314        
Issuance of common shares, net of issuance costs $ 2,644       2,644
Issuance of common shares, net of issuance costs (shares) 361,236        
Share-based compensation     6,905   6,905
Closing balance at Sep. 30, 2022 $ 254,937 $ 52,941 22,441 (253,164) 77,155
Balance at the end of period (in shares) at Sep. 30, 2022 30,388,109 12,327,780      
Increase (Decrease) in Stockholders' Equity          
Number of warrants   12,327,780      
Opening balance at Jun. 30, 2022 $ 252,236 $ 52,941 20,090 (238,608) 86,659
Balance at the beginning of period (in shares) at Jun. 30, 2022 30,005,884        
Increase (Decrease) in Stockholders' Equity          
Net loss       (14,556) (14,556)
Exercise of stock options $ 57   (29)   28
Exercise of stock options (in shares) 20,989        
Issuance of common shares, net of issuance costs $ 2,644       2,644
Issuance of common shares, net of issuance costs (shares) 361,236        
Share-based compensation     2,380   2,380
Closing balance at Sep. 30, 2022 $ 254,937 $ 52,941 22,441 (253,164) $ 77,155
Balance at the end of period (in shares) at Sep. 30, 2022 30,388,109 12,327,780      
Increase (Decrease) in Stockholders' Equity          
Number of warrants   12,327,780      
Number of warrants         8,518,257
Opening balance at Dec. 31, 2022 $ 273,900 $ 34,352 24,437 (266,341) $ 66,348
Balance at the beginning of period (in shares) at Dec. 31, 2022 34,286,002 8,518,257     34,286,002
Increase (Decrease) in Stockholders' Equity          
Net loss       (46,074) $ (46,074)
Exercise of stock options $ 324   (136)   188
Exercise of stock options (in shares) 112,779        
Private placement   $ 14,107     14,107
Private placement (in shares)   1,059,000      
Share-based compensation     7,657   7,657
Cancellation of common shares $ (14,115)       (14,115)
Cancellation of common shares (in shares) (1,059,000)        
Employee stock purchase plan purchases $ 393       393
Employee stock purchase plan purchases (in shares) 142,006        
Closing balance at Sep. 30, 2023 $ 260,502 $ 48,459 31,958 (312,415) $ 28,504
Balance at the end of period (in shares) at Sep. 30, 2023 33,481,787 9,577,257     33,481,787
Increase (Decrease) in Stockholders' Equity          
Number of warrants   9,577,257      
Opening balance at Jun. 30, 2023 $ 260,169 $ 48,459 29,114 (297,334) $ 40,408
Balance at the beginning of period (in shares) at Jun. 30, 2023 33,363,971        
Increase (Decrease) in Stockholders' Equity          
Net loss       (15,081) (15,081)
Exercise of stock options $ 68   (28)   40
Exercise of stock options (in shares) 18,798        
Share-based compensation     2,872   2,872
Employee stock purchase plan purchases $ 265       265
Employee stock purchase plan purchases (in shares) 99,018        
Closing balance at Sep. 30, 2023 $ 260,502 $ 48,459 $ 31,958 $ (312,415) $ 28,504
Balance at the end of period (in shares) at Sep. 30, 2023 33,481,787 9,577,257     33,481,787
Increase (Decrease) in Stockholders' Equity          
Number of warrants   9,577,257     9,577,257
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows used in operating activities    
Net loss $ (46,074) $ (45,211)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 66 74
Amortization of debt costs 160  
Accretion of investment discount (79)  
Non-cash interest expense related to debt 1,537  
Share-based compensation expense 7,657 6,905
Changes in operating assets and liabilities:    
Other receivables (639) (308)
Research and development tax credits receivable (238) 161
Prepaid expenses (956) (759)
Operating lease assets and liabilities (2) 47
Accounts payable and accrued liabilities 1,940 (516)
Net cash used in operating activities (36,628) (39,607)
Cash provided by (used in) investing activities    
Acquisition of property and equipment (81) (162)
Acquisition of short-term investments (95,839) (62,947)
Redemption of short-term investments 87,000 23,000
Net cash used in investing activities (8,920) (40,109)
Cash provided by financing activities    
Proceeds from exercise of options 188 217
Proceeds from issuance of senior secured convertible debt 50,000  
Issuance of common shares, net of issuance costs   2,644
Pre-funded warrant issuance costs (8)  
Proceeds from employee stock purchase plan 393  
Payment of debt issuance costs (2,782)  
Cash provided by financing activities 47,791 2,861
Net increase (decrease) in cash and cash equivalents 2,243 (76,855)
Cash and cash equivalents - Beginning of period 7,636 114,141
Cash and cash equivalents - End of period $ 9,879 $ 37,286
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Organization and Nature of Operations
9 Months Ended
Sep. 30, 2023
Organization and Nature of Operations  
Organization and Nature of Operations

1    Organization and Nature of Operations

Milestone Pharmaceuticals Inc. (Milestone or the Company) is a biopharmaceutical company incorporated under the Business Corporations Act (Québec). Milestone is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate, etripamil, is a novel, potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2023
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2     Summary of Significant Accounting Policies

a)  Basis of Consolidation

The consolidated financial statements include the accounts of the Company and Milestone Pharmaceuticals USA, Inc. All intercompany transactions and balances have been eliminated.

b)  Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies

These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or “US GAAP”, and on a basis consistent with those accounting principles followed by the Company and disclosed in Note 2 of its most recent annual consolidated financial statements. Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with US GAAP have been omitted or condensed.  Accordingly, these unaudited interim condensed consolidated financial statements do not include all the information required for full annual financial statements, and therefore, should be read in conjunction with the annual consolidated financial statements and the notes thereto for the year ended December 31, 2022.

In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its balance sheet as of September 30, 2023, and its statements of loss and shareholders’ equity for the three and nine months ended September 30, 2023 and 2022 and its statements of cash flows for the nine months ended September 30, 2023 and 2022.

The condensed consolidated balance sheet as of December 31, 2022, was derived from audited annual consolidated financial statements, but does not contain all the footnote disclosures required by accounting principles generally accepted in the United States of America.

These unaudited interim condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.

The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to,

Estimates of the percentage of work completed of the total work over the life of an individual clinical trial in accordance with agreements established with contracted research organizations, or “CRO”, contracted
manufacturing organizations, or “CMO”, and clinical trial sites which in turn impact the research & development expenses.
Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.

c) Significant Risks and Uncertainties

The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements.  

Further, the Company may be impacted by general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international armed conflicts and overall fluctuations in the financial markets in the United States and abroad.

d) Recent Accounting Pronouncements

The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

e) Sources of Liquidity and Funding Requirements

The Company incurred operating losses and has experienced negative operating cash flows since its inception  and anticipates to continue to incur losses for at least the next several years. As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million. Management has evaluated the Company’s operating plan against its existing cash and cash equivalents and determined that the Company expects to be able to support its operations for at least the next 12 months from the date of issuance of these unaudited interim consolidated financial statements.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Revenues
9 Months Ended
Sep. 30, 2023
Revenues  
Revenues

3     Revenues

The Company recorded no revenue for the three months ended September 30, 2023 and $1.0 million in revenue during the nine months ended September 30, 2023. This revenue is due to a milestone reached as a result of the successful initiation of a Phase 1 Clinical Trial of the product by or on behalf of Ji Xing for the treatment of paroxysmal supraventricular tachycardia, or “PSVT”, in the Territory. The Company recorded $1.5 million in revenue for the three and nine months ended September 30, 2022. This revenue was related to a milestone reached as a result of the first patient dosed in a Phase 3 Clinical Trial for the treatment of PSVT in the Territory. For details on the arrangement with Ji Xing, see Note 3 to our audited consolidated financial statements for the year ended December 31, 2022, filed on Form 10-K.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Short-term Investments
9 Months Ended
Sep. 30, 2023
Short-term Investments  
Short-term Investments

4     Short-term Investments

Short term investments are classified as held-to-maturity, are initially recognized at fair value and are subsequently accounted for at amortized cost. They are comprised of guaranteed investment certificates with a maturity greater than 90 days but less than one year and, as such, are classified as current assets.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
9 Months Ended
Sep. 30, 2023
Debt  
Debt

5     Debt

On March 27, 2023, we entered into a note purchase agreement, or the “Note Purchase Agreement”, with RTW Investments LP and certain of its affiliates, or collectively, RTW.

On March 29, 2023, we closed the transactions contemplated by the Note Purchase Agreement, and issued and sold $50.0 million principal amount of 6.0% Convertible Senior Notes due 2029, or the “2029 Convertible Notes”, to the holders.

The 2029 Convertible Notes are senior secured obligations and are guaranteed on a senior secured basis by our wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc. Interest at the annual rate of 6.0% is payable quarterly in cash or, at our option, payable in kind for the first three years. The maturity date for the 2029 Convertible Notes is March 31, 2029, the “Maturity Date”. The obligations under the 2029 Convertible Notes are secured by substantially all of our and our subsidiary guarantor’s assets.

Each $1,000 of principal of the 2029 Convertible Notes (including any interest added thereto as payment in kind) is convertible into 191.0548 shares of our common shares, equivalent to an initial conversion price of approximately $5.23 per share, subject to customary anti-dilution and other adjustments. In addition, following a notice of redemption or certain corporate events that occur prior to the Maturity Date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2029 Convertible Notes in connection with such notice of redemption or corporate event.

On or after March 27, 2027, the 2029 Convertible Notes are redeemable by us, subject to certain conditions, if the closing sale price of the common shares exceeds 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

In accounting for the issuance of the Convertible Notes, the Company determined there were no embedded features, which require bifurcation between debt and equity components. As a result, the Convertible Notes are accounted for as a liability. As of September 30, 2023, the estimated fair value of the Convertible Notes was approximately $51.4 million.

The net carrying amount of the Convertible Note were as follows:

    

September 30, 2023

December 31, 2022

Original principal

 

$

50,000

$

Paid in kind (PIK) interest

1,537

Unamortized debt discount

(566)

Unamortized debt issuance costs

 

(2,056)

Total

 

$

48,915

$

The following table presents the total amount of interest cost recognized relating to the 2029 Convertible Notes (in thousands):

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Contractual interest expense

$

762

 

$

$

1,537

 

$

Amortization of debt discount

16

34

Amortization of debt issuance costs

63

 

126

 

Total interest expense

$

841

 

$

$

1,697

 

$

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Liabilities
9 Months Ended
Sep. 30, 2023
Accounts Payable and Accrued Liabilities  
Accounts Payable and Accrued Liabilities

6    Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of the following:  

    

September 30, 2023

December 31, 2022

    

  

 

  

Trade accounts payable

 

$

1,855

$

2,263

Accrued compensation and benefits payable

 

2,426

2,573

Accrued research and development liabilities

 

2,051

404

Other accrued liabilities

 

1,252

404

Total

 

$

7,584

$

5,644

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity
9 Months Ended
Sep. 30, 2023
Shareholders' Equity  
Shareholders' Equity

7      Shareholders’ Equity

Authorized Share Capital

The Company has authorized and issued common shares, voting and participating, without par value, of which unlimited shares were authorized and 33,481,787 shares were issued and outstanding as of September 30, 2023.

As of September 30, 2023, there were 1,463,936 common shares available for issuance under the Employee Stock Purchase Plan, or the “ESPP”. The Company has issued 142,006 shares of common stock pursuant to the ESPP as of September 30, 2023.

On March 22, 2023, the Company entered into an exchange agreement, or the “Exchange Agreement”, with entities affiliated with RTW, or the Exchanging Stockholders, pursuant to which the Company exchanged an aggregate of 1,059,000 shares of the Company’s common shares owned by the Exchanging Stockholders for pre-funded warrants, or the Exchange Warrants, to purchase an aggregate of 1,059,000 common shares, with an exercise price of $0.001 per share and no expiration date. The Exchange Warrants are exercisable immediately and no additional cash consideration was rendered in exchange for the warrants. A holder of the Exchange Warrants (together with its affiliates and other attribution parties) may not exercise any portion of an Exchange Warrant to the extent that immediately prior to or after giving effect to such exercise the holder, together with its affiliates, would beneficially own more than 9.99% of the Company’s outstanding common shares immediately after exercise, which percentage may be increased or decreased to any other percentage specified not in excess of 9.99% at the holder's election upon 61 days'  notice to the Company subject to the terms of the Exchange Warrants.

Additional Paid-in Capital

The additional paid-in capital balances were as follows:

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Opening balance

$

29,114

 

$

20,090

$

24,437

 

$

15,711

Share-based compensation expense

2,872

 

2,380

7,657

 

6,905

Exercise of stock options

(28)

 

(29)

(136)

 

(175)

Closing balance

$

31,958

 

$

22,441

$

31,958

 

$

22,441

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation
9 Months Ended
Sep. 30, 2023
Share Based Compensation  
Share Based Compensation

8     Share Based Compensation

Under the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) and the Company’s Stock Option Plan (the “2011 Plan”), unless otherwise decided by the Board of Directors, options vest and are exercisable as follows: 25% vest and are exercisable on the one year anniversary of the grant date and one thirty-sixth (1/36th) of the remaining options vest and are exercisable each month thereafter, such that options are vested in full on four-year anniversary of the grant date.

On January 1, 2023 and on January 1, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,371,440 and 1,195,902 common shares, respectively. Further, on July 5, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,000,000 common shares. In addition, 125,323 options have been forfeited under the 2011 Plan since the adoption of the 2019 Plan and have become available for issuance under the 2019 Plan. As of September 30, 2023, 561,000 of previously issued options had been cancelled under the 2019 Plan and were available for future grants.  As of September 30, 2023, there were 8,182,946 common shares available for issuance under the 2019 Plan, of which 1,644,623 common shares were available for future grants.

On November 10, 2021, the Company established a 2021 Inducement Plan (the “Inducement Plan”) through the granting of awards. This 2021 Inducement Plan is intended to help the Company provide an inducement material for certain individuals to enter into employment with the Company, incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which employees may benefit from increases in value of the common shares. As of September 30, 2023, there were 1,000,000 shares available for issuance under the 2021 Inducement Plan, of which 497,000 shares were available for future grants.

On July 15, 2022, the Company offered an ESPP, in which participation is available to substantially all of our employees in the United States and Canada who meet certain service eligibility requirements. On January 1, 2023 the number of common shares reserved for issuance under the ESPP increased by 342,860 shares. As of September 30, 2023, the Company has 1,463,936 common shares available for issuance under the ESPP. As of September 30, 2023, the Company has issued 142,006 shares of common stock pursuant to the ESPP.

The total outstanding and exercisable options from the 2011 Plan, 2019 Plan and Inducement Plan as of September 30 were as follows:

2023

Weighted

Number

average

of shares

exercise

    

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

 

    

1,802,672

    

1,802,672

    

$

2.05

Outstanding at beginning of year - 2019 Plan

5,314,312

5,314,312

8.35

Outstanding at beginning of year - Inducement Plan

503,000

503,000

6.41

Granted - 2019 Plan

1,867,400

1,867,400

3.62

Exercised - 2019 Plan

(7,000)

(7,000)

3.74

Exercised - 2011 Plan

(105,779)

(105,779)

1.52

Forfeited - 2019 Plan

(87,861)

(87,861)

6.28

Expired - 2019 Plan

(58,617)

(58,617)

11.52

Expired - 2011 Plan

(343)

(343)

0.92

Cancelled - 2019 Plan

(561,000)

(561,000)

21.73

Outstanding at end of period

 

6,467,234

503,000

1,696,550

8,666,784

$

5.13

Outstanding at end of period - Weighted average exercise price

$

5.83

$

6.41

$

2.08

Exercisable at end of period

2,972,614

190,396

1,696,550

4,859,560

$

5.25

Exercisable at end of period - Weighted average exercise price

 

$

6.98

$

6.42

$

2.08

2022

Weighted

Number

average

of shares

exercise

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

    

1,995,971

1,995,971

$

2.07

Outstanding at beginning of year - 2019 Plan

 

3,759,834

3,759,834

9.51

Granted - 2019 Plan

1,748,700

1,748,700

5.78

Granted - Inducement Plan

523,000

523,000

6.37

Exercised - 2019 Plan

(15,089)

(15,089)

3.92

Exercised - 2011 Plan

(114,225)

(114,225)

1.38

Forfeited - 2019 Plan

(17,950)

(17,950)

14.31

Forfeited - 2011 Plan

(19,387)

(19,387)

9.42

Expired - 2011 Plan

(1,121)

(1,121)

0.96

Outstanding at end of period

5,475,495

523,000

1,861,238

7,859,733

$

6.70

Outstanding at end of period - Weighted average exercise price

$

8.32

$

6.37

$

2.04

Exercisable at end of period

2,219,125

1,831,482

4,050,607

$

6.28

Exercisable at end of period - Weighted average exercise price

$

9.79

$

2.01

The weighted average remaining contractual life was 7.5 and 7.8 years for outstanding options as of September 30, 2023 and 2022, respectively. The weighted average remaining contractual life was 6.4 and 6.7 years for vested options, as of September 30, 2023 and 2022, respectively.

There was $13.2 million and $18.6 million of total unrecognized compensation cost related to non-vested share options as of September 30, 2023 and 2022, respectively. The share options are expected to be recognized over a remaining weighted average vesting period of 2.4 years and 2.5 years as of September 30, 2023 and 2022, respectively. For the three and nine months ended September 30, 2023, there were 561,000 shares cancelled under the 2019 plan, which resulted in additional share-based compensation expense of $0.6 million.  

Options granted are valued using the Black-Scholes option pricing model. Amortization of the fair value of the options over vesting years has been expensed and credited to additional paid-in capital in shareholders’ equity.

The non-vested options as of September 30 were as follows:

2023

Number

Weighted

of options

average

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

    

 

2,126

2,126

 

$

6.64

Non-vested share options at beginning of year - 2019 Plan

2,923,763

2,923,763

 

5.30

Non-vested share options at beginning of year - Inducement Plan

503,000

503,000

4.84

Granted - 2019 Plan

 

1,867,400

1,867,400

2.87

Vested, outstanding 2011 Plan

(2,126)

(2,126)

 

6.64

Vested, outstanding 2019 Plan

(1,231,712)

(1,231,712)

6.09

Vested, outstanding Inducement Plan

(190,396)

(190,396)

4.85

Forfeited - 2019 Plan

(64,831)

(64,831)

4.08

Non-vested share options at end of period

 

3,494,620

312,604

3,807,224

 

$

3.83

Non-vested share options at end of period - Weighted average fair value

$

3.74

$

4.84

$

2022

Number

Weighted

of options

average

    

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

 

200,639

200,639

 

$

1.86

Non-vested share options at beginning of year - 2019 Plan

2,665,518

2,665,518

 

6.39

Granted - 2019 Plan

 

1,748,700

1,748,700

4.37

Granted - Inducement Plan

523,000

523,000

4.81

Vested, outstanding 2011 Plan

(170,883)

(170,883)

 

1.76

Forfeited - 2019 Plan

(8,731)

(8,731)

6.27

Vested, outstanding 2019 Plan

(1,149,117)

(1,149,117)

5.99

Non-vested share options at end of period

 

3,256,370

523,000

29,756

3,809,126

 

$

5.34

Non-vested share options at end of period - Weighted average fair value

$

5.45

$

4.81

$

2.44

The fair value of share-based payment transactions is measured using Black-Scholes valuation model. This model also requires assumptions, including expected option life, volatility, risk-free interest rate and dividend yield, which greatly affect the calculated values.

The fair value of options granted for the 2011 Plan, 2019 Plan and Inducement Plan were estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

 

2023

    

2022

 

Exercise price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Share price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Volatility

 

98

%  

93

%

 

98

%  

91

%

Risk-free interest rate

 

4.09

%  

2.94

%

 

3.92

%  

2.41

%

Expected life

 

6.08 years

 

5.75 years

 

6.00 years

 

6.03 years

Dividend

 

0

%  

0

%

 

0

%  

0

%

Expected volatility is determined using comparable companies for which the information is publicly available. The risk-free interest rate is determined based on the U.S. sovereign rates benchmark in effect at the time of grant with a remaining term equal to the expected life of the option. Expected option life is determined based on the simplified method as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The simplified method is an average of the contractual term of the options and its ordinary vesting period. Dividend yield is based on the share option’s exercise price and expected annual dividend rate at the time of grant.

The Company recognized share-based compensation expense as follows:

Three months ended September 30, 

Nine months ended September 30, 

    

2023

    

2022

2023

    

2022

    

Administration

 

$

1,546

$

1,891

$

4,051

 

$

3,683

Research and development

 

900

349

2,526

 

2,302

Commercial activities

 

426

140

1,080

 

920

Total

 

$

2,872

$

2,380

$

7,657

 

$

6,905

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share
9 Months Ended
Sep. 30, 2023
Net Loss Per Share  
Net Loss Per Share

9     Net Loss Per Share

Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and pre-funded warrants outstanding during the period.

For the three and nine months ended September 30, 2023 and 2022, the Company was in a net loss position. Dilutive net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and shares issuable upon exercise of pre-funded warrants outstanding during the period. In addition to the conversion feature on the 2029 Convertible Notes described above, which the Company reviewed and concluded would be anti-dilutive due to the facts surrounding the feature, the following potentially dilutive securities have also been excluded from the computation of diluted weighted average shares outstanding as of September 30, as they would be anti-dilutive:

    

2023

    

2022

Share options

 

8,666,784

 

7,859,733

Amounts above reflect the common share equivalents of the noted instruments.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Royalty Purchase Agreement
9 Months Ended
Sep. 30, 2023
Royalty Purchase Agreement  
Royalty Purchase Agreement

10     Royalty Purchase Agreement

On March 27, 2023, we entered into a purchase and sale agreement, or the “Royalty Purchase Agreement”, with RTW and certain of its affiliates.

Pursuant to the Royalty Purchase Agreement, RTW agreed to purchase, following the U.S. Food and Drug Administration approval of etripamil (subject to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments, or the “Royalty Interest”,  on the annual net product sales of etripamil in the United States in an amount equal to: (i) 7%, or the “Initial Tier Royalty”, of annual net sales up to $500 million, (ii) 4% of annual net sales greater than $500 million and less than or equal to $800 million, and (iii) 1% of annual net sales greater than $800 million. If certain revenue thresholds for aggregate annual net sales are not met, the Initial Tier Royalty will increase to 9.5% beginning on January 1 of the following calendar year until a subsequent sales threshold is attained, at which time the Initial Tier Royalty would revert back to 7%.

Based on the Company’s assessment of the terms and conditions under the Royalty Purchase Agreement, there is no accounting recognition required in these interim financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2023
Summary of Significant Accounting Policies  
Basis of Consolidation

a)  Basis of Consolidation

The consolidated financial statements include the accounts of the Company and Milestone Pharmaceuticals USA, Inc. All intercompany transactions and balances have been eliminated.

Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies

b)  Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies

These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or “US GAAP”, and on a basis consistent with those accounting principles followed by the Company and disclosed in Note 2 of its most recent annual consolidated financial statements. Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with US GAAP have been omitted or condensed.  Accordingly, these unaudited interim condensed consolidated financial statements do not include all the information required for full annual financial statements, and therefore, should be read in conjunction with the annual consolidated financial statements and the notes thereto for the year ended December 31, 2022.

In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its balance sheet as of September 30, 2023, and its statements of loss and shareholders’ equity for the three and nine months ended September 30, 2023 and 2022 and its statements of cash flows for the nine months ended September 30, 2023 and 2022.

The condensed consolidated balance sheet as of December 31, 2022, was derived from audited annual consolidated financial statements, but does not contain all the footnote disclosures required by accounting principles generally accepted in the United States of America.

These unaudited interim condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.

The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to,

Estimates of the percentage of work completed of the total work over the life of an individual clinical trial in accordance with agreements established with contracted research organizations, or “CRO”, contracted
manufacturing organizations, or “CMO”, and clinical trial sites which in turn impact the research & development expenses.
Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.
Significant Risks and Uncertainties

c) Significant Risks and Uncertainties

The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements.  

Further, the Company may be impacted by general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international armed conflicts and overall fluctuations in the financial markets in the United States and abroad.

Recent Accounting Pronouncements

d) Recent Accounting Pronouncements

The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.

Sources of Liquidity and Funding Requirements

e) Sources of Liquidity and Funding Requirements

The Company incurred operating losses and has experienced negative operating cash flows since its inception  and anticipates to continue to incur losses for at least the next several years. As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million. Management has evaluated the Company’s operating plan against its existing cash and cash equivalents and determined that the Company expects to be able to support its operations for at least the next 12 months from the date of issuance of these unaudited interim consolidated financial statements.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Tables)
9 Months Ended
Sep. 30, 2023
Debt  
Schedule of Convertible Note

    

September 30, 2023

December 31, 2022

Original principal

 

$

50,000

$

Paid in kind (PIK) interest

1,537

Unamortized debt discount

(566)

Unamortized debt issuance costs

 

(2,056)

Total

 

$

48,915

$

Schedule of total amount of interest cost

The following table presents the total amount of interest cost recognized relating to the 2029 Convertible Notes (in thousands):

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Contractual interest expense

$

762

 

$

$

1,537

 

$

Amortization of debt discount

16

34

Amortization of debt issuance costs

63

 

126

 

Total interest expense

$

841

 

$

$

1,697

 

$

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Liabilities (Tables)
9 Months Ended
Sep. 30, 2023
Accounts Payable and Accrued Liabilities  
Schedule of accounts payable and accrued liabilities

    

September 30, 2023

December 31, 2022

    

  

 

  

Trade accounts payable

 

$

1,855

$

2,263

Accrued compensation and benefits payable

 

2,426

2,573

Accrued research and development liabilities

 

2,051

404

Other accrued liabilities

 

1,252

404

Total

 

$

7,584

$

5,644

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Shareholders' Equity  
Schedule of additional paid-in capital

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

    

2023

    

2022

Opening balance

$

29,114

 

$

20,090

$

24,437

 

$

15,711

Share-based compensation expense

2,872

 

2,380

7,657

 

6,905

Exercise of stock options

(28)

 

(29)

(136)

 

(175)

Closing balance

$

31,958

 

$

22,441

$

31,958

 

$

22,441

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share Based Compensation  
Schedule of outstanding and exercisable options

2023

Weighted

Number

average

of shares

exercise

    

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

 

    

1,802,672

    

1,802,672

    

$

2.05

Outstanding at beginning of year - 2019 Plan

5,314,312

5,314,312

8.35

Outstanding at beginning of year - Inducement Plan

503,000

503,000

6.41

Granted - 2019 Plan

1,867,400

1,867,400

3.62

Exercised - 2019 Plan

(7,000)

(7,000)

3.74

Exercised - 2011 Plan

(105,779)

(105,779)

1.52

Forfeited - 2019 Plan

(87,861)

(87,861)

6.28

Expired - 2019 Plan

(58,617)

(58,617)

11.52

Expired - 2011 Plan

(343)

(343)

0.92

Cancelled - 2019 Plan

(561,000)

(561,000)

21.73

Outstanding at end of period

 

6,467,234

503,000

1,696,550

8,666,784

$

5.13

Outstanding at end of period - Weighted average exercise price

$

5.83

$

6.41

$

2.08

Exercisable at end of period

2,972,614

190,396

1,696,550

4,859,560

$

5.25

Exercisable at end of period - Weighted average exercise price

 

$

6.98

$

6.42

$

2.08

2022

Weighted

Number

average

of shares

exercise

2019 Plan

   

Inducement Plan

2011 Plan

   

Total

   

price

Outstanding at beginning of year - 2011 Plan

    

1,995,971

1,995,971

$

2.07

Outstanding at beginning of year - 2019 Plan

 

3,759,834

3,759,834

9.51

Granted - 2019 Plan

1,748,700

1,748,700

5.78

Granted - Inducement Plan

523,000

523,000

6.37

Exercised - 2019 Plan

(15,089)

(15,089)

3.92

Exercised - 2011 Plan

(114,225)

(114,225)

1.38

Forfeited - 2019 Plan

(17,950)

(17,950)

14.31

Forfeited - 2011 Plan

(19,387)

(19,387)

9.42

Expired - 2011 Plan

(1,121)

(1,121)

0.96

Outstanding at end of period

5,475,495

523,000

1,861,238

7,859,733

$

6.70

Outstanding at end of period - Weighted average exercise price

$

8.32

$

6.37

$

2.04

Exercisable at end of period

2,219,125

1,831,482

4,050,607

$

6.28

Exercisable at end of period - Weighted average exercise price

$

9.79

$

2.01

Schedule of non-vested share options activity

2023

Number

Weighted

of options

average

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

    

 

2,126

2,126

 

$

6.64

Non-vested share options at beginning of year - 2019 Plan

2,923,763

2,923,763

 

5.30

Non-vested share options at beginning of year - Inducement Plan

503,000

503,000

4.84

Granted - 2019 Plan

 

1,867,400

1,867,400

2.87

Vested, outstanding 2011 Plan

(2,126)

(2,126)

 

6.64

Vested, outstanding 2019 Plan

(1,231,712)

(1,231,712)

6.09

Vested, outstanding Inducement Plan

(190,396)

(190,396)

4.85

Forfeited - 2019 Plan

(64,831)

(64,831)

4.08

Non-vested share options at end of period

 

3,494,620

312,604

3,807,224

 

$

3.83

Non-vested share options at end of period - Weighted average fair value

$

3.74

$

4.84

$

2022

Number

Weighted

of options

average

    

2019 Plan

    

Inducement Plan

    

2011 Plan

    

Total

    

fair value

Non-vested share options at beginning of year - 2011 Plan

 

200,639

200,639

 

$

1.86

Non-vested share options at beginning of year - 2019 Plan

2,665,518

2,665,518

 

6.39

Granted - 2019 Plan

 

1,748,700

1,748,700

4.37

Granted - Inducement Plan

523,000

523,000

4.81

Vested, outstanding 2011 Plan

(170,883)

(170,883)

 

1.76

Forfeited - 2019 Plan

(8,731)

(8,731)

6.27

Vested, outstanding 2019 Plan

(1,149,117)

(1,149,117)

5.99

Non-vested share options at end of period

 

3,256,370

523,000

29,756

3,809,126

 

$

5.34

Non-vested share options at end of period - Weighted average fair value

$

5.45

$

4.81

$

2.44

Schedule of weighted average assumptions for the options granted

Three months ended September 30, 

Nine months ended September 30, 

2023

    

2022

 

2023

    

2022

 

Exercise price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Share price

$

3.14

 

$

6.94

$

3.62

 

$

5.91

Volatility

 

98

%  

93

%

 

98

%  

91

%

Risk-free interest rate

 

4.09

%  

2.94

%

 

3.92

%  

2.41

%

Expected life

 

6.08 years

 

5.75 years

 

6.00 years

 

6.03 years

Dividend

 

0

%  

0

%

 

0

%  

0

%

Schedule of share-based compensation expense

Three months ended September 30, 

Nine months ended September 30, 

    

2023

    

2022

2023

    

2022

    

Administration

 

$

1,546

$

1,891

$

4,051

 

$

3,683

Research and development

 

900

349

2,526

 

2,302

Commercial activities

 

426

140

1,080

 

920

Total

 

$

2,872

$

2,380

$

7,657

 

$

6,905

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share (Tables)
9 Months Ended
Sep. 30, 2023
Net Loss Per Share  
Schedule of potentially dilutive securities excluded from the computation of diluted weighted average shares

    

2023

    

2022

Share options

 

8,666,784

 

7,859,733

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Summary of Significant Accounting Policies    
Cash, cash equivalents and short-term investments $ 75,700  
Accumulated deficit $ (312,415) $ (266,341)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues        
Revenue $ 0 $ 1,500 $ 1,000 $ 1,500
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Debt (Details)
9 Months Ended
Mar. 29, 2023
USD ($)
item
$ / shares
shares
Sep. 30, 2023
USD ($)
Debt Instruments    
Proceeds from convertible notes   $ 50,000,000
Debt issuance costs paid   2,782,000
RTW Investments, LP | Senior Secured Convertible Notes | Strategic Financing Agreements    
Debt Instruments    
Proceeds from convertible notes $ 50,000,000.0  
Coupon rate (as a percent) 6.00%  
Paid in kind, term 3 years  
Principal amount denomination for conversion $ 1,000  
Convertible shares issuable | shares 191.0548  
Conversion price | $ / shares $ 5.23  
Threshold Percentage of stock price 150.00%  
Threshold trading days | item 20  
Threshold consecutive trading days | item 30  
Redemption price percentage 100.00%  
Estimated Fair Value   $ 51,400,000
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Convertible Note (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Instrument [Line Items]  
Total $ 48,915
Senior Secured Convertible Notes | RTW Investments, LP | Strategic Financing Agreements  
Debt Instrument [Line Items]  
Original principal 50,000
Paid in kind (PIK) interest 1,537
Unamortized debt discount (566)
Unamortized debt issuance costs (2,056)
Total $ 48,915
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Total amount of interest cost (Details) - Senior Secured Convertible Notes - RTW Investments, LP - Strategic Financing Agreements - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Debt Instrument [Line Items]    
Contractual interest expense $ 762 $ 1,537
Amortization of debt discount 16 34
Amortization of debt issuance costs 63 126
Total interest expense $ 841 $ 1,697
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Accounts Payable and Accrued Liabilities    
Trade accounts payable $ 1,855 $ 2,263
Accrued compensation and benefits payable 2,426 2,573
Accrued research and development liabilities 2,051 404
Other accrued liabilities 1,252 404
Total $ 7,584 $ 5,644
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity - Authorized share capital (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Authorized share capital      
Common Stock, Shares, Issued 33,481,787   34,286,002
Common Stock, Shares, Outstanding 33,481,787   34,286,002
Issuance of common shares, net of issuance costs   $ 2,644  
Employee Stock Purchase Plan      
Authorized share capital      
Number of common shares available for issuance 1,463,936    
Number of shares issued under the ESPP 142,006    
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 22, 2023
Sep. 30, 2022
Sep. 30, 2022
Class of Warrant or Right      
Net proceeds     $ 2,644,000
Offering price   $ 2,644,000 $ 2,644,000
RTW Investments, LP      
Class of Warrant or Right      
Purchase price $ 0.001    
Common shares exchanged for pre-funded warrants 1,059,000    
Proceeds from exercise of warrants $ 0    
Maximum ownership after exercise of exchange agreement 9.99%    
Required notice (in days) 61 days    
Common Shares      
Class of Warrant or Right      
Number of shares issued during the period   361,236 361,236
Offering price   $ 2,644,000 $ 2,644,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Shareholders' Equity - Additional paid-in capital (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Additional paid-in capital        
Opening balance $ 40,408 $ 86,659 $ 66,348 $ 112,600
Share-based compensation expense 2,872 2,380 7,657 6,905
Exercise of stock options 40 28 188 217
Closing balance 28,504 77,155 28,504 77,155
Additional paid-in capital        
Additional paid-in capital        
Opening balance 29,114 20,090 24,437 15,711
Share-based compensation expense 2,872 2,380 7,657 6,905
Exercise of stock options (28) (29) (136) (175)
Closing balance $ 31,958 $ 22,441 $ 31,958 $ 22,441
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation (Details) - $ / shares
3 Months Ended 9 Months Ended
Jan. 01, 2022
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Jan. 01, 2023
Dec. 31, 2022
Jul. 05, 2022
Dec. 31, 2021
2011 Plan                
Share-based compensation                
Number of options forfeited after termination of one plan 125,323              
Number of options, Options outstanding   1,696,550 1,696,550 1,861,238   1,802,672   1,995,971
Weighted average exercise price     $ 0.92          
2019 Plan                
Share-based compensation                
Shares reserved for issuance 1,195,902 8,182,946 8,182,946   1,371,440   1,000,000  
Shares available for future grants   1,644,623 1,644,623          
Options granted     1,867,400 1,748,700        
Cancelled   561,000 561,000          
Number of options, Options outstanding   6,467,234 6,467,234 5,475,495   5,314,312   3,759,834
Weighted average exercise price     $ 3.62 $ 5.78        
2021 Inducement Plan                
Share-based compensation                
Shares reserved for issuance   1,000,000 1,000,000          
Shares available for future grants   497,000 497,000          
Options granted       523,000        
Number of options, Options outstanding   503,000 503,000 523,000   503,000    
Weighted average exercise price       $ 6.37        
ESPP                
Share-based compensation                
Shares reserved for issuance   1,463,936 1,463,936   342,860      
Shares issued     142,006          
Options | 2011 Plan                
Share-based compensation                
Vesting period     4 years          
Options | 2011 Plan | Share-based Compensation Award, Tranche One                
Share-based compensation                
Percentage of shares to vest     25.00%          
Options | 2011 Plan | Share-based Compensation Award, Tranche Two                
Share-based compensation                
Percentage of shares to vest     2.78%          
Options | 2019 Plan                
Share-based compensation                
Vesting period     4 years          
Options | 2019 Plan | Share-based Compensation Award, Tranche One                
Share-based compensation                
Percentage of shares to vest     25.00%          
Options | 2019 Plan | Share-based Compensation Award, Tranche Two                
Share-based compensation                
Percentage of shares to vest     2.78%          
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation - Outstanding and exercisable options (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Outstanding and exercisable options, weighted average exercise price        
Weighted average remaining contractual life (in years)     7 years 6 months 7 years 9 months 18 days
Weighted average remaining contractual life for vested options (in years)     6 years 4 months 24 days 6 years 8 months 12 days
Unrecognized compensation cost $ 13,200 $ 18,600 $ 13,200 $ 18,600
Expected period for recognition     2 years 4 months 24 days 2 years 6 months
Share-based compensation expense $ 2,872 $ 2,380 $ 7,657 $ 6,905
Plans 2011 and 2019 and 2021 Inducement [Member]        
Outstanding and exercisable options, number of shares        
Outstanding at end of period 8,666,784 7,859,733 8,666,784 7,859,733
Exercisable at end of period 4,859,560 4,050,607 4,859,560 4,050,607
Outstanding and exercisable options, weighted average exercise price        
Outstanding at end of period $ 5.13 $ 6.70 $ 5.13 $ 6.70
Exercisable at end of period $ 5.25 $ 6.28 $ 5.25 $ 6.28
2011 Plan        
Outstanding and exercisable options, number of shares        
Outstanding at beginning of period     1,802,672 1,995,971
Expired     (343) (1,121)
Exercised     (105,779) (114,225)
Forfeited       (19,387)
Outstanding at end of period 1,696,550 1,861,238 1,696,550 1,861,238
Exercisable at end of period 1,696,550 1,831,482 1,696,550 1,831,482
Outstanding and exercisable options, weighted average exercise price        
Outstanding at beginning of period     $ 2.05 $ 2.07
Granted     0.92  
Exercised     1.52 1.38
Forfeited       9.42
Expired       0.96
Outstanding at end of period $ 2.08 $ 2.04 2.08 2.04
Exercisable at end of period $ 2.08 $ 2.01 $ 2.08 $ 2.01
2019 Plan        
Outstanding and exercisable options, number of shares        
Outstanding at beginning of period     5,314,312 3,759,834
Granted     1,867,400 1,748,700
Expired     (58,617)  
Exercised     (7,000) (15,089)
Forfeited     (87,861) (17,950)
Cancelled (561,000)   (561,000)  
Outstanding at end of period 6,467,234 5,475,495 6,467,234 5,475,495
Exercisable at end of period 2,972,614 2,219,125 2,972,614 2,219,125
Outstanding and exercisable options, weighted average exercise price        
Outstanding at beginning of period     $ 8.35 $ 9.51
Granted     3.62 5.78
Exercised     3.74 3.92
Forfeited     6.28 14.31
Cancelled     21.73  
Expired     11.52  
Outstanding at end of period $ 5.83 $ 8.32 5.83 8.32
Exercisable at end of period $ 6.98 $ 9.79 $ 6.98 $ 9.79
Share-based compensation expense $ 600   $ 600  
2021 Inducement Plan        
Outstanding and exercisable options, number of shares        
Outstanding at beginning of period     503,000  
Granted       523,000
Outstanding at end of period 503,000 523,000 503,000 523,000
Exercisable at end of period 190,396   190,396  
Outstanding and exercisable options, weighted average exercise price        
Outstanding at beginning of period     $ 6.41  
Granted       $ 6.37
Outstanding at end of period $ 6.41 $ 6.37 6.41 $ 6.37
Exercisable at end of period $ 6.42   $ 6.42  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation - Non-vested share options (Details) - $ / shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Plans 2011 and 2019 and 2021 Inducement [Member]    
Number of options    
Non-vested share options at end of period 3,807,224 3,809,126
Weighted average fair value    
Non-vested at end of period $ 3.83 $ 5.34
2011 Plan    
Number of options    
Non-vested at beginning of period 2,126 200,639
Vested, outstanding (2,126) (170,883)
Non-vested share options at end of period   29,756
Weighted average fair value    
Non-vested at beginning of period $ 6.64 $ 1.86
Vested, outstanding $ 6.64 1.76
Non-vested at end of period   $ 2.44
2019 Plan    
Number of options    
Non-vested at beginning of period 2,923,763 2,665,518
Granted 1,867,400 1,748,700
Vested, outstanding (1,231,712) (1,149,117)
Forfeited (64,831) (8,731)
Non-vested share options at end of period 3,494,620 3,256,370
Weighted average fair value    
Non-vested at beginning of period $ 5.30 $ 6.39
Granted 2.87 4.37
Vested, outstanding 6.09 5.99
Forfeited 4.08 6.27
Non-vested at end of period $ 3.74 $ 5.45
2021 Inducement Plan    
Number of options    
Non-vested at beginning of period 503,000  
Granted   523,000
Vested, outstanding (190,396)  
Non-vested share options at end of period 312,604 523,000
Weighted average fair value    
Non-vested at beginning of period $ 4.84  
Granted   $ 4.81
Vested, outstanding 4.85  
Non-vested at end of period $ 4.84 $ 4.81
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation - Weighted average assumptions for the options granted (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share Based Compensation        
Exercise price $ 3.14 $ 6.94 $ 3.62 $ 5.91
Share price (in dollars per share) $ 3.14 $ 6.94 $ 3.62 $ 5.91
Volatility (as a percent) 98.00% 93.00% 98.00% 91.00%
Risk-free interest rate (as a percent) 4.09% 2.94% 3.92% 2.41%
Expected life (in years) 6 years 29 days 5 years 9 months 6 years 6 years 10 days
Dividend (as a percent) 0.00% 0.00% 0.00% 0.00%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Share Based Compensation - Recognized share-based compensation expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-based compensation        
Share-based compensation expense $ 2,872 $ 2,380 $ 7,657 $ 6,905
Administration        
Share-based compensation        
Share-based compensation expense 1,546 1,891 4,051 3,683
Research and development        
Share-based compensation        
Share-based compensation expense 900 349 2,526 2,302
Commercial activities        
Share-based compensation        
Share-based compensation expense $ 426 $ 140 $ 1,080 $ 920
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share options    
Net income (loss) per share    
Share options 8,666,784 7,859,733
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Royalty Purchase Agreement (Details) - RTW Investments, LP - Strategic Financing Agreements
$ in Millions
Mar. 27, 2023
USD ($)
Royalty Purchase Agreement  
Funding received from sale of product rights $ 75.0
Up to $500 million  
Royalty Purchase Agreement  
Future payment as a percentage of aggregate net sales 7.00%
Threshold amount of annual aggregate net sales $ 500.0
Additional future payment as a percentage of aggregate net sales 9.50%
Above $800 million  
Royalty Purchase Agreement  
Future payment as a percentage of aggregate net sales 1.00%
Threshold amount of annual aggregate net sales $ 800.0
Minimum | Above $500 million  
Royalty Purchase Agreement  
Future payment as a percentage of aggregate net sales 4.00%
Threshold amount of annual aggregate net sales $ 500.0
Maximum | Up to $800 million  
Royalty Purchase Agreement  
Future payment as a percentage of aggregate net sales 4.00%
Threshold amount of annual aggregate net sales $ 800.0
XML 50 mist-20230930x10q_htm.xml IDEA: XBRL DOCUMENT 0001408443 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001408443 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001408443 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001408443 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001408443 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001408443 mist:EmployeeStockPurchasePlanMember 2023-01-01 2023-09-30 0001408443 us-gaap:RetainedEarningsMember 2023-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001408443 us-gaap:RetainedEarningsMember 2023-06-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001408443 2023-06-30 0001408443 us-gaap:RetainedEarningsMember 2022-12-31 0001408443 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001408443 us-gaap:RetainedEarningsMember 2022-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001408443 us-gaap:RetainedEarningsMember 2022-06-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001408443 2022-06-30 0001408443 us-gaap:RetainedEarningsMember 2021-12-31 0001408443 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001408443 mist:InducementPlanMember 2023-01-01 2023-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2022-12-31 0001408443 mist:InducementPlanMember 2022-12-31 0001408443 mist:EquityIncentivePlan2019Member 2022-12-31 0001408443 mist:InducementPlanMember 2022-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2021-12-31 0001408443 mist:EquityIncentivePlan2019Member 2021-12-31 0001408443 mist:RestatedShareOptionPlan2011Member 2023-01-01 2023-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2022-01-01 2022-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2023-09-30 0001408443 mist:Plans2011And2019And2021InducementMember 2023-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2022-09-30 0001408443 mist:Plans2011And2019And2021InducementMember 2022-09-30 0001408443 mist:EquityIncentivePlan2019Member 2022-09-30 0001408443 us-gaap:EmployeeStockMember 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:RestatedShareOptionPlan2011Member us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:RestatedShareOptionPlan2011Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:EquityIncentivePlan2019Member us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:EquityIncentivePlan2019Member us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:RestatedShareOptionPlan2011Member 2023-01-01 2023-09-30 0001408443 us-gaap:EmployeeStockOptionMember mist:EquityIncentivePlan2019Member 2023-01-01 2023-09-30 0001408443 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001408443 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001408443 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001408443 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001408443 us-gaap:CommonStockMember 2023-09-30 0001408443 us-gaap:CommonStockMember 2023-06-30 0001408443 us-gaap:CommonStockMember 2022-12-31 0001408443 mist:PreFundedWarrantMember 2022-12-31 0001408443 us-gaap:CommonStockMember 2022-09-30 0001408443 us-gaap:CommonStockMember 2022-06-30 0001408443 us-gaap:CommonStockMember 2021-12-31 0001408443 mist:PreFundedWarrantMember 2021-12-31 0001408443 mist:InducementPlanMember 2023-09-30 0001408443 mist:EquityIncentivePlan2019Member 2023-09-30 0001408443 mist:EmployeeStockPurchasePlanMember 2023-09-30 0001408443 mist:EquityIncentivePlan2019Member 2023-01-01 0001408443 mist:EmployeeStockPurchasePlanMember 2023-01-01 0001408443 mist:EquityIncentivePlan2019Member 2022-07-05 0001408443 mist:EquityIncentivePlan2019Member 2022-01-01 0001408443 mist:PreFundedWarrantMember 2023-09-30 0001408443 mist:PreFundedWarrantMember 2023-06-30 0001408443 mist:PreFundedWarrantMember 2022-09-30 0001408443 mist:PreFundedWarrantMember 2022-06-30 0001408443 2022-09-30 0001408443 2021-12-31 0001408443 us-gaap:StockCompensationPlanMember 2023-01-01 2023-09-30 0001408443 us-gaap:StockCompensationPlanMember 2022-01-01 2022-09-30 0001408443 mist:RtwInvestmentsLpMember us-gaap:ConvertibleDebtMember mist:StrategicFinancingAgreementsMember 2023-07-01 2023-09-30 0001408443 mist:RtwInvestmentsLpMember us-gaap:ConvertibleDebtMember mist:StrategicFinancingAgreementsMember 2023-01-01 2023-09-30 0001408443 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001408443 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001408443 mist:CommercialActivitiesMember 2023-07-01 2023-09-30 0001408443 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001408443 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001408443 mist:CommercialActivitiesMember 2023-01-01 2023-09-30 0001408443 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001408443 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001408443 mist:CommercialActivitiesMember 2022-07-01 2022-09-30 0001408443 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001408443 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001408443 mist:CommercialActivitiesMember 2022-01-01 2022-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001408443 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001408443 mist:PreFundedWarrantMember 2023-01-01 2023-09-30 0001408443 mist:InducementPlanMember 2022-01-01 2022-09-30 0001408443 mist:EquityIncentivePlan2019Member 2022-01-01 2022-09-30 0001408443 mist:RestatedShareOptionPlan2011Member 2022-01-01 2022-01-01 0001408443 mist:EquityIncentivePlan2019Member 2023-07-01 2023-09-30 0001408443 mist:EquityIncentivePlan2019Member 2023-01-01 2023-09-30 0001408443 mist:RtwInvestmentsLpMember srt:MinimumMember mist:AggregateNetSalesAbove500MillionMember mist:StrategicFinancingAgreementsMember 2023-03-27 2023-03-27 0001408443 mist:RtwInvestmentsLpMember srt:MaximumMember mist:AggregateNetSalesUpTo800MillionMember mist:StrategicFinancingAgreementsMember 2023-03-27 2023-03-27 0001408443 mist:RtwInvestmentsLpMember mist:AggregateNetSalesAbove800MillionMember mist:StrategicFinancingAgreementsMember 2023-03-27 2023-03-27 0001408443 mist:RtwInvestmentsLpMember mist:StrategicFinancingAgreementsMember 2023-03-27 2023-03-27 0001408443 mist:RtwInvestmentsLpMember us-gaap:ConvertibleDebtMember mist:StrategicFinancingAgreementsMember 2023-03-29 2023-03-29 0001408443 mist:RtwInvestmentsLpMember us-gaap:ConvertibleDebtMember mist:StrategicFinancingAgreementsMember 2023-09-30 0001408443 mist:RtwInvestmentsLpMember us-gaap:ConvertibleDebtMember mist:StrategicFinancingAgreementsMember 2023-03-29 0001408443 mist:RtwInvestmentsLpMember 2023-03-22 0001408443 2023-07-01 2023-09-30 0001408443 2022-07-01 2022-09-30 0001408443 2022-01-01 2022-09-30 0001408443 2022-01-01 2022-12-31 0001408443 mist:RtwInvestmentsLpMember 2023-03-22 2023-03-22 0001408443 mist:RtwInvestmentsLpMember mist:AggregateNetSalesUpTo500MillionMember mist:StrategicFinancingAgreementsMember 2023-03-27 2023-03-27 0001408443 2023-09-30 0001408443 2022-12-31 0001408443 2023-11-13 0001408443 2023-01-01 2023-09-30 shares iso4217:USD pure iso4217:USD shares mist:item 0001408443 --12-31 2023 Q3 false 33481787 34286002 A8 00-0000000 Unlimited Unlimited 9577257 0.25 P4Y 8518257 33481787 0.0278 0.04 0.0278 10-Q true 2023-09-30 false 001-38899 Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal QC CA H4M 2X6 514 336-0444 Common Shares MIST NASDAQ Yes Yes Non-accelerated Filer true true true false 33483111 9879000 7636000 65867000 56949000 569000 331000 6961000 6005000 1521000 882000 84797000 71803000 2047000 2423000 272000 257000 87116000 74483000 7584000 5644000 530000 495000 8114000 6139000 1583000 1996000 48915000 58612000 8135000 0 0 33481787 34286002 260502000 273900000 9577257 8518257 48459000 34352000 31958000 24437000 -312415000 -266341000 28504000 66348000 87116000 74483000 1500000 1000000 1500000 6721000 9826000 25600000 29251000 4227000 4034000 12561000 11595000 4412000 2670000 10137000 6537000 -15360000 -15030000 -47298000 -45883000 1120000 474000 2921000 672000 841000 1697000 -15081000 -14556000 -46074000 -45211000 42973160 42973160 42491787 42491787 42920620 42920620 42339123 42339123 -0.35 -0.35 -0.34 -0.34 -1.07 -1.07 -1.07 -1.07 30005884 252236000 12327780 52941000 20090000 -238608000 86659000 -14556000 -14556000 20989 57000 -29000 28000 2380000 2380000 361236 2644000 2644000 30388109 254937000 12327780 52941000 22441000 -253164000 77155000 33363971 260169000 9577257 48459000 29114000 -297334000 40408000 -15081000 -15081000 18798 68000 -28000 40000 2872000 2872000 99018 265000 265000 33481787 260502000 9577257 48459000 31958000 -312415000 28504000 29897559 251901000 12327780 52941000 15711000 -207953000 112600000 -45211000 -45211000 129314 392000 -175000 217000 6905000 6905000 361236 2644000 2644000 30388109 254937000 12327780 52941000 22441000 -253164000 77155000 34286002 273900000 8518257 34352000 24437000 -266341000 66348000 -46074000 -46074000 112779 324000 -136000 188000 1059000 14107000 14107000 7657000 7657000 1059000 14115000 14115000 142006 393000 393000 33481787 260502000 9577257 48459000 31958000 -312415000 28504000 -46074000 -45211000 66000 74000 160000 -79000 1537000 7657000 6905000 639000 308000 238000 -161000 956000 759000 -2000 47000 1940000 -516000 -36628000 -39607000 81000 162000 95839000 62947000 -87000000 -23000000 -8920000 -40109000 188000 217000 50000000 2644000 8000 393000 2782000 47791000 2861000 2243000 -76855000 7636000 114141000 9879000 37286000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1    Organization and Nature of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Milestone Pharmaceuticals Inc. (Milestone or the Company) is a biopharmaceutical company incorporated under the <i style="font-style:italic;">Business Corporations Act</i> (Québec). Milestone is focused on the development and commercialization of cardiovascular medicines. Milestone’s lead product candidate, etripamil, is a novel, potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">2     Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">a)  Basis of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and Milestone Pharmaceuticals USA, Inc. All intercompany transactions and balances have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">b)  Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or “US GAAP”, and on a basis consistent with those accounting principles followed by the Company and disclosed in Note 2 of its most recent annual consolidated financial statements. Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with US GAAP have been omitted or condensed.  Accordingly, these unaudited interim condensed consolidated financial statements do not include all the information required for full annual financial statements, and therefore, should be read in conjunction with the annual consolidated financial statements and the notes thereto for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its balance sheet as of September 30, 2023, and its statements of loss and shareholders’ equity for the three and nine months ended September 30, 2023 and 2022 and its statements of cash flows for the nine months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated balance sheet as of December 31, 2022, was derived from audited annual consolidated financial statements, but does not contain all the footnote disclosures required by accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to, </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimates of the percentage of work completed of the total work over the life of an individual clinical trial in accordance with agreements established with contracted research organizations, or “CRO”, contracted </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing organizations, or “CMO”, and clinical trial sites which in turn impact the research &amp; development expenses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">c) Significant Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman;">The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements. </span><span style="font-family:'Times New Roman;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman;font-weight:normal;">Further, the Company may be impacted by general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation</span><span style="font-family:'Times New Roman;font-weight:normal;">, international armed conflicts</span><span style="font-family:'Times New Roman;font-weight:normal;"> and overall fluctuations in the financial markets in the U</span><span style="font-family:'Times New Roman;font-weight:normal;">nited States</span><span style="font-family:'Times New Roman;font-weight:normal;"> and abroad.</span><span style="font-family:'Times New Roman;font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">d) Recent Accounting Pronouncements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">e) Sources of Liquidity and Funding Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred operating losses and has experienced negative operating cash flows since its inception  and anticipates to continue to incur losses for at least the next several years. As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million. Management has evaluated the Company’s operating plan against its existing cash and cash equivalents and determined that the Company expects to be able to support its operations for at least the next 12 months from the date of issuance of these unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">a)  Basis of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of the Company and Milestone Pharmaceuticals USA, Inc. All intercompany transactions and balances have been eliminated.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">b)  Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or “US GAAP”, and on a basis consistent with those accounting principles followed by the Company and disclosed in Note 2 of its most recent annual consolidated financial statements. Certain information, in particular the accompanying notes normally included in the annual financial statements prepared in accordance with US GAAP have been omitted or condensed.  Accordingly, these unaudited interim condensed consolidated financial statements do not include all the information required for full annual financial statements, and therefore, should be read in conjunction with the annual consolidated financial statements and the notes thereto for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the opinion of the Company's management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its balance sheet as of September 30, 2023, and its statements of loss and shareholders’ equity for the three and nine months ended September 30, 2023 and 2022 and its statements of cash flows for the nine months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated balance sheet as of December 31, 2022, was derived from audited annual consolidated financial statements, but does not contain all the footnote disclosures required by accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements are presented in US dollars, which is the Company’s functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates and judgments include, but are not limited to, </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimates of the percentage of work completed of the total work over the life of an individual clinical trial in accordance with agreements established with contracted research organizations, or “CRO”, contracted </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing organizations, or “CMO”, and clinical trial sites which in turn impact the research &amp; development expenses.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Estimate of the grant date fair value share options granted to employees, consultants and directors, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model.</span></td></tr></table><div style="margin-top:12pt;"></div> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">c) Significant Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman;">The Company is subject to challenges and risks specific to its business and its ability to execute on its strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidate; delays or problems in the supply of its study drug or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and complying with applicable regulatory requirements. </span><span style="font-family:'Times New Roman;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">​</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman;font-weight:normal;">Further, the Company may be impacted by general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation</span><span style="font-family:'Times New Roman;font-weight:normal;">, international armed conflicts</span><span style="font-family:'Times New Roman;font-weight:normal;"> and overall fluctuations in the financial markets in the U</span><span style="font-family:'Times New Roman;font-weight:normal;">nited States</span><span style="font-family:'Times New Roman;font-weight:normal;"> and abroad.</span><span style="font-family:'Times New Roman;font-weight:normal;"> </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">d) Recent Accounting Pronouncements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has considered recent accounting pronouncements and concluded that they are either not applicable to the business or that the effect is not expected to be material to the unaudited condensed consolidated financial statements as a result of future adoption.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">e) Sources of Liquidity and Funding Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred operating losses and has experienced negative operating cash flows since its inception  and anticipates to continue to incur losses for at least the next several years. As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of $75.7 million and an accumulated deficit of $312.4 million. Management has evaluated the Company’s operating plan against its existing cash and cash equivalents and determined that the Company expects to be able to support its operations for at least the next 12 months from the date of issuance of these unaudited interim consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 75700000 -312400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:6pt 0pt 0pt 0pt;">3     Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The Company recorded no revenue for the three months ended September 30, 2023 and $1.0 million in revenue during the nine months ended September 30, 2023. This revenue is due to a milestone reached as a result of the successful initiation of a Phase 1 Clinical Trial of the product by or on behalf of Ji Xing for the treatment of paroxysmal supraventricular tachycardia, or “PSVT”, in the Territory. The Company recorded $1.5 million in revenue for the three and nine months ended September 30, 2022. This revenue was related to a milestone reached as a result of the first patient dosed in a Phase 3 Clinical Trial for the treatment of PSVT in the Territory. For details on the arrangement with Ji Xing, see Note 3 to our audited consolidated financial statements for the year ended December 31, 2022, filed on Form 10-K.</p> 0 1000000.0 1500000 1500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;padding-top:6pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;">4     Short-term Investments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Short term investments are classified as held-to-maturity, are initially recognized at fair value and are subsequently accounted for at amortized cost. They are comprised of guaranteed investment certificates with a maturity greater than 90 days but less than one year and, as such, are classified as current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">5</b><b style="font-weight:bold;">     Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, we entered into a note purchase agreement, or the “Note Purchase Agreement”, with <span style="font-family:'Times New Roman;">RTW Investments LP and certain of its affiliates, or collectively, RTW</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, we closed the transactions contemplated by the Note Purchase Agreement, and issued and sold $50.0 million principal amount of 6.0% Convertible Senior Notes due 2029, or the “2029 Convertible Notes”, to the holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2029 Convertible Notes are senior secured obligations and are guaranteed on a senior secured basis by our wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc. Interest at the annual rate of 6.0% is payable quarterly in cash or, at our option, payable in kind for the first three years. The maturity date for the 2029 Convertible Notes is March 31, 2029, the “Maturity Date”. The obligations under the 2029 Convertible Notes are secured by substantially all of our and our subsidiary guarantor’s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each $1,000 of principal of the 2029 Convertible Notes (including any interest added thereto as payment in kind) is convertible into 191.0548 shares of our common shares, equivalent to an initial conversion price of approximately $5.23 per share, subject to customary anti-dilution and other adjustments. In addition, following a notice of redemption or certain corporate events that occur prior to the Maturity Date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2029 Convertible Notes in connection with such notice of redemption or corporate event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or after March 27, 2027, the 2029 Convertible Notes are redeemable by us, subject to certain conditions, if the closing sale price of the common shares exceeds 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In accounting for the issuance of the Convertible Notes, the Company determined there were no embedded features, which require bifurcation between debt and equity components. As a result, the Convertible Notes are accounted for as a liability. As of September 30, 2023, the estimated fair value of the Convertible Notes was approximately $51.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The net carrying amount of the Convertible Note were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Original principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Paid in kind (PIK) interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unamortized debt discount </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (566)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (2,056)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the total amount of interest cost recognized relating to the 2029 Convertible Notes (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:top;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Amortization of debt discount</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Amortization of debt issuance costs </p></td><td style="vertical-align:top;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 50000000.0 0.060 0.060 P3Y 1000 191.0548 5.23 1.50 20 30 1 51400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Original principal </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Paid in kind (PIK) interest </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unamortized debt discount </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (566)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Unamortized debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (2,056)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:45.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,915</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table> 50000000 1537000 566000 2056000 48915000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents the total amount of interest cost recognized relating to the 2029 Convertible Notes (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:top;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Amortization of debt discount</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Amortization of debt issuance costs </p></td><td style="vertical-align:top;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:30.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:top;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 841</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:30.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 762000 1537000 16000 34000 63000 126000 841000 1697000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;">6    Accounts Payable and Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;">Accounts payable and accrued liabilities are comprised of the following:  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:top;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Trade accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,263</p></td></tr><tr><td style="vertical-align:top;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accrued compensation and benefits payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,573</p></td></tr><tr><td style="vertical-align:top;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accrued research and development liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:top;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:bottom;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,644</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">  </b></p></td></tr><tr><td style="vertical-align:top;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Trade accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,263</p></td></tr><tr><td style="vertical-align:top;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accrued compensation and benefits payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,573</p></td></tr><tr><td style="vertical-align:top;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accrued research and development liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:top;width:67.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:bottom;width:67.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,644</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 1855000 2263000 2426000 2573000 2051000 404000 1252000 404000 7584000 5644000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">7      Shareholders’ Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Authorized Share Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has authorized and issued common shares, voting and participating, without par value, of which unlimited shares were authorized and 33,481,787 shares were issued and <span style="-sec-ix-hidden:Hidden_cbgcK2IxfUy42J1BScfFZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2023, there were <span style="background:#ffffff;">1,463,936</span> common shares available for issuance under the Employee Stock Purchase Plan, or the “ESPP”. The Company has issued 142,006 shares of common stock pursuant to the ESPP as of September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">On March</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">22, 2023, the Company entered into an exchange agreement, or</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">the “Exchange Agreement”, with entities affiliated with RTW, or</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">the </span><span style="font-family:'Times New Roman;">“</span><span style="font-family:'Times New Roman;">Exchanging Stockholders</span><span style="font-family:'Times New Roman;">”</span><span style="font-family:'Times New Roman;">, pursuant to which the Company exchanged an aggregate of </span><span style="font-family:'Times New Roman;">1,059,000</span><span style="font-family:'Times New Roman;"> shares of the Company’s common shares owned by the Exchanging Stockholders</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">for</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">pre-funded</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">warrants, or</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">the</span><span style="font-family:'Times New Roman;"> </span><span style="font-family:'Times New Roman;">Exchange Warrants, to purchase an aggregate of </span><span style="font-family:'Times New Roman;">1,059,000</span><span style="font-family:'Times New Roman;"> common shares, with an exercise price of </span><span style="font-family:'Times New Roman;">$0.001</span><span style="font-family:'Times New Roman;"> per share and no expiration date. The Exchange Warrants are exercisable immediately and </span><span style="font-family:'Times New Roman;">no</span><span style="font-family:'Times New Roman;"> additional cash consideration was rendered in exchange for the warrants. A holder of the Exchange Warrants (together with its affiliates and other attribution parties) may not exercise any portion of an Exchange Warrant to the extent that immediately prior to or after giving effect to such exercise the holder, together with its affiliates, would beneficially own more than </span><span style="font-family:'Times New Roman;">9.99%</span><span style="font-family:'Times New Roman;"> of the Company’s outstanding common shares immediately after exercise, which percentage may be increased or decreased to any other percentage specified not in excess of </span><span style="font-family:'Times New Roman;">9.99%</span><span style="font-family:'Times New Roman;"> at the holder's election upon </span><span style="font-family:'Times New Roman;">61 days</span><span style="font-family:'Times New Roman;">'  notice to the Company subject to the terms of the Exchange Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Additional Paid-in Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The additional paid-in capital balances were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 33481787 1463936 142006 1059000 1059000 0.001 0 0.0999 0.0999 P61D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Opening balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20,090</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:42.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Closing balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr></table> 29114000 20090000 24437000 15711000 2872000 2380000 7657000 6905000 -28000 -29000 -136000 -175000 31958000 22441000 31958000 22441000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">8     Share Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) and the Company’s Stock Option Plan (the “2011 Plan”), unless otherwise decided by the Board of Directors, options vest and are exercisable as follows: 25% <span style="-sec-ix-hidden:Hidden_IrsJRJ9ym0O2F_hnAkxqqg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vest</span></span> and are exercisable on the one year anniversary of the grant date and <span style="-sec-ix-hidden:Hidden_PINIh2rMY0q_sZTqjM6ONQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one thirty-sixth</span></span> (1/36<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>) of the <span style="-sec-ix-hidden:Hidden_2n2dX6PxmEiJwFDSlC-BeA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">remaining</span></span> options vest and are exercisable each month thereafter, such that options are vested in full on four-year <span style="-sec-ix-hidden:Hidden_ES6XwhuPFEivRY3RrRwzhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anniversary</span></span> of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 1, 2023 and on January 1, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,371,440 and 1,195,902 common shares, respectively. Further, on July 5, 2022, the number of the Company’s common shares reserved for issuance under the 2019 Plan increased by 1,000,000 common shares. In addition, 125,323 options have been forfeited under the 2011 Plan since the adoption of the 2019 Plan and have become available for issuance under the 2019 Plan. As of September 30, 2023, 561,000 of previously issued options had been cancelled under the 2019 Plan and were available for future grants.  As of September 30, 2023, there were 8,182,946 common shares available for issuance under the 2019 Plan, of which 1,644,623 common shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 10, 2021, the Company established a 2021 Inducement Plan (the “Inducement Plan”) through the granting of awards. This 2021 Inducement Plan is intended to help the Company provide an inducement material for certain individuals to enter into employment with the Company, incentives for such persons to exert maximum efforts for the success of the Company and provide a means by which employees may benefit from increases in value of the common shares. As of September 30, 2023, there were 1,000,000 shares available for issuance under the 2021 Inducement Plan, of which 497,000 shares were available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 15, 2022, the Company offered an ESPP, in which participation is available to substantially all of our employees in the United States and Canada who meet certain service eligibility requirements. On January 1, 2023 the number of common shares reserved for issuance under the ESPP increased by 342,860 shares. As of September 30, 2023, the Company has 1,463,936 common shares available for issuance under the ESPP. As of September 30, 2023, the Company has issued 142,006 shares of common stock pursuant to the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The total outstanding and exercisable options from the 2011 Plan, 2019 Plan and Inducement Plan as of September 30 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="12" style="vertical-align:bottom;white-space:nowrap;width:61.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,802,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,802,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.05</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,314,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,314,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.35</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.41</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.62</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.74</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.52</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,861)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,861)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.28</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.52</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.92</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cancelled - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.73</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,467,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,666,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,972,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,859,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.25</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="12" style="vertical-align:bottom;white-space:nowrap;width:61.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.51</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.78</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,089)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,089)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.38</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,950)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,950)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.31</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.42</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.96</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,475,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,861,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,859,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.70</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,219,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,831,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.28</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The weighted average remaining contractual life was 7.5 and 7.8 years for outstanding options as of September 30, 2023 and 2022, respectively. The weighted average remaining contractual life was 6.4 and 6.7 years for vested options, as of September 30, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There was $13.2 million and $18.6 million of total unrecognized compensation cost related to non-vested share options as of September 30, 2023 and 2022, respectively. The share options are expected to be recognized over a remaining weighted average vesting period of 2.4 years and 2.5 years as of September 30, 2023 and 2022, respectively. For the three and nine months ended September 30, 2023, there were 561,000 shares cancelled under the 2019 plan, which resulted in additional share-based compensation expense of $0.6 million.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Options granted are valued using the Black-Scholes option pricing model. Amortization of the fair value of the options over vesting years has been expensed and credited to additional paid-in capital in shareholders’ equity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The non-vested options as of September 30 were as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2011 Plan</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.64</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.30</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - Inducement Plan </p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.84</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.87</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.64</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,231,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,231,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.09</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding Inducement Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (190,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (190,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.85</p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (64,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (64,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.08</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.83</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period - Weighted average fair value</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.86</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,665,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,665,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.39</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.37</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - Inducement Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.81</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (170,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (170,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.27</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,149,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,149,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.99</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,256,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,809,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.34</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period - Weighted average fair value</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of share-based payment transactions is measured using Black-Scholes valuation model. This model also requires assumptions, including expected option life, volatility, risk-free interest rate and dividend yield, which greatly affect the calculated values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of options granted for the 2011 Plan, 2019 Plan and Inducement Plan were estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for the options granted:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">6.08</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">5.75</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> </span><span style="font-size:9pt;">6.00</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">6.03</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected volatility is determined using comparable companies for which the information is publicly available. The risk-free interest rate is determined based on the U.S. sovereign rates benchmark in effect at the time of grant with a remaining term equal to the expected life of the option. Expected option life is determined based on the simplified method as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The simplified method is an average of the contractual term of the options and its ordinary vesting period. Dividend yield is based on the share option’s exercise price and expected annual dividend rate at the time of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recognized share-based compensation expense as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:top;width:39.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Commercial activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 0.25 P4Y 1371440 1195902 1000000 125323 561000 8182946 1644623 1000000 497000 342860 1463936 142006 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="12" style="vertical-align:bottom;white-space:nowrap;width:61.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,802,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,802,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.05</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,314,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,314,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.35</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.41</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.62</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.74</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.52</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,861)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (87,861)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.28</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,617)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.52</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.92</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cancelled - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.73</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,467,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,666,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,972,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 190,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,696,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,859,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.25</p></td></tr><tr><td style="vertical-align:bottom;width:36.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="12" style="vertical-align:bottom;white-space:nowrap;width:61.24%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:41.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">   </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,995,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.07</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,759,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.51</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.78</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Granted - Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,089)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15,089)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercised - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (114,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.38</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,950)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,950)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.31</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.42</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Expired - 2011 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.96</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,475,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,861,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,859,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.70</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,219,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,831,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.28</p></td></tr><tr><td style="vertical-align:bottom;width:36.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of period - Weighted average exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table> 1802672 1802672 2.05 5314312 5314312 8.35 503000 503000 6.41 1867400 1867400 3.62 7000 7000 3.74 105779 105779 1.52 87861 87861 6.28 58617 58617 11.52 343 343 0.92 561000 561000 21.73 6467234 503000 1696550 8666784 5.13 5.83 6.41 2.08 2972614 190396 1696550 4859560 5.25 6.98 6.42 2.08 1995971 1995971 2.07 3759834 3759834 9.51 1748700 1748700 5.78 523000 523000 6.37 15089 15089 3.92 114225 114225 1.38 17950 17950 14.31 19387 19387 9.42 1121 1121 0.96 5475495 523000 1861238 7859733 6.70 8.32 6.37 2.04 2219125 1831482 4050607 6.28 9.79 2.01 P7Y6M P7Y9M18D P6Y4M24D P6Y8M12D 13200000 18600000 P2Y4M24D P2Y6M 561000 561000 600000 600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2011 Plan</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.64</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,923,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.30</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - Inducement Plan </p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 503,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.84</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,867,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.87</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (2,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.64</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,231,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,231,712)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.09</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding Inducement Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (190,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (190,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.85</p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (64,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (64,831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.08</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,494,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 312,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807,224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.83</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period - Weighted average fair value</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inducement Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2011 Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 200,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.86</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at beginning of year - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,665,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,665,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.39</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.37</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Granted - Inducement Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.81</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2011 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (170,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (170,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.76</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forfeited - 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (8,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.27</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vested, outstanding 2019 Plan</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,149,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (1,149,117)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.99</p></td></tr><tr><td style="vertical-align:top;width:41.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,256,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 523,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,809,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.34</p></td></tr><tr><td style="vertical-align:top;width:41.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-vested share options at end of period - Weighted average fair value</p></td><td style="vertical-align:top;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr></table> 2126 2126 6.64 2923763 2923763 5.30 503000 503000 4.84 1867400 1867400 2.87 2126 2126 6.64 1231712 1231712 6.09 190396 190396 4.85 64831 64831 4.08 3494620 312604 3807224 3.83 3.74 4.84 200639 200639 1.86 2665518 2665518 6.39 1748700 1748700 4.37 523000 523000 4.81 170883 170883 1.76 8731 8731 6.27 1149117 1149117 5.99 3256370 523000 29756 3809126 5.34 5.45 4.81 2.44 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:44.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">6.08</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">5.75</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;"> </span><span style="font-size:9pt;">6.00</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9pt;">6.03</span><span style="font-size:9pt;"> years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:44.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Dividend</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">%</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">%</p></td></tr></table> 3.14 6.94 3.62 5.91 3.14 6.94 3.62 5.91 0.98 0.93 0.98 0.91 0.0409 0.0294 0.0392 0.0241 P6Y29D P5Y9M P6Y P6Y10D 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:top;width:39.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:39.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Commercial activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,905</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 1546000 1891000 4051000 3683000 900000 349000 2526000 2302000 426000 140000 1080000 920000 2872000 2380000 7657000 6905000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">9     Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Basic net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and pre-funded warrants outstanding during the period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">For the three and nine months ended September 30, 2023 and 2022, the Company was in a net loss position. Dilutive net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted average number of common shares and shares issuable upon exercise of pre-funded warrants outstanding during the period. In addition to the conversion feature on the 2029 Convertible Notes described above, which the Company reviewed and concluded would be anti-dilutive due to the facts surrounding the feature, the following potentially dilutive securities have also been excluded from the computation of diluted weighted average shares outstanding as of September 30, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,666,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,859,733</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amounts above reflect the common share equivalents of the noted instruments.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Share options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,666,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,859,733</p></td></tr></table> 8666784 7859733 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">10     Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 27, 2023, we entered into a purchase and sale agreement, or the “Royalty Purchase Agreement”, with RTW and certain of its affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Royalty Purchase Agreement, RTW agreed to purchase, following the U.S. Food and Drug Administration approval of etripamil (subject to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments, or the “Royalty Interest”,  on the annual net product sales of etripamil in the United States in an amount equal to: (i) 7%, or the “Initial Tier Royalty”, of annual net sales up to $500 million, (ii) 4% of annual net sales <span style="-sec-ix-hidden:Hidden_NfevQIk7HE6ScraxxKzMIg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">greater</span></span> than $500 million and less than or equal to $800 million, and (iii) 1% of annual net sales greater than $800 million. If certain revenue thresholds for aggregate annual net sales are not met, the Initial Tier Royalty will increase to 9.5% beginning on January 1 of the following calendar year until a subsequent sales threshold is attained, at which time the Initial Tier Royalty would revert back to 7%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman;">Based on the Company’s assessment of the terms and conditions under the Royalty Purchase Agreement, there is no accounting recognition required in these interim financial statements.</span></p> 75000000.0 0.07 500000000 0.04 500000000 800000000 0.01 800000000 0.095 0.07 EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 110 202 1 false 26 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Loss Sheet http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss Condensed Consolidated Statements of Loss Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Organization and Nature of Operations Sheet http://www.milestonepharma.com/role/DisclosureOrganizationAndNatureOfOperations Organization and Nature of Operations Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Revenues Sheet http://www.milestonepharma.com/role/DisclosureRevenues Revenues Notes 9 false false R10.htm 10401 - Disclosure - Short-term Investments Sheet http://www.milestonepharma.com/role/DisclosureShortTermInvestments Short-term Investments Notes 10 false false R11.htm 10501 - Disclosure - Debt Sheet http://www.milestonepharma.com/role/DisclosureDebt Debt Notes 11 false false R12.htm 10601 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 12 false false R13.htm 10701 - Disclosure - Shareholders' Equity Sheet http://www.milestonepharma.com/role/DisclosureShareholdersEquity Shareholders' Equity Notes 13 false false R14.htm 10801 - Disclosure - Share Based Compensation Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensation Share Based Compensation Notes 14 false false R15.htm 10901 - Disclosure - Net Loss Per Share Sheet http://www.milestonepharma.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 11001 - Disclosure - Royalty Purchase Agreement Sheet http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreement Royalty Purchase Agreement Notes 16 false false R17.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 30503 - Disclosure - Debt (Tables) Sheet http://www.milestonepharma.com/role/DisclosureDebtTables Debt (Tables) Tables http://www.milestonepharma.com/role/DisclosureDebt 18 false false R19.htm 30603 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities 19 false false R20.htm 30703 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.milestonepharma.com/role/DisclosureShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.milestonepharma.com/role/DisclosureShareholdersEquity 20 false false R21.htm 30803 - Disclosure - Share Based Compensation (Tables) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables Share Based Compensation (Tables) Tables http://www.milestonepharma.com/role/DisclosureShareBasedCompensation 21 false false R22.htm 30903 - Disclosure - Net loss per share (Tables) Sheet http://www.milestonepharma.com/role/DisclosureNetLossPerShareTables Net loss per share (Tables) Tables 22 false false R23.htm 40201 - Disclosure - Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details) Sheet http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSourcesOfLiquidityAndFundingRequirementsDetails Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details) Details 23 false false R24.htm 40301 - Disclosure - Revenue (Details) Sheet http://www.milestonepharma.com/role/DisclosureRevenueDetails Revenue (Details) Details http://www.milestonepharma.com/role/DisclosureRevenues 24 false false R25.htm 40501 - Disclosure - Debt (Details) Sheet http://www.milestonepharma.com/role/DisclosureDebtDetails Debt (Details) Details http://www.milestonepharma.com/role/DisclosureDebtTables 25 false false R26.htm 40502 - Disclosure - Debt - Convertible Note (Details) Sheet http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails Debt - Convertible Note (Details) Details 26 false false R27.htm 40503 - Disclosure - Debt - Total amount of interest cost (Details) Sheet http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails Debt - Total amount of interest cost (Details) Details 27 false false R28.htm 40601 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables 28 false false R29.htm 40701 - Disclosure - Shareholders' Equity - Authorized share capital (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails Shareholders' Equity - Authorized share capital (Details) Details 29 false false R30.htm 40702 - Disclosure - Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details) Details 30 false false R31.htm 40703 - Disclosure - Shareholders' Equity - Additional paid-in capital (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails Shareholders' Equity - Additional paid-in capital (Details) Details 31 false false R32.htm 40801 - Disclosure - Share Based Compensation (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails Share Based Compensation (Details) Details http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables 32 false false R33.htm 40802 - Disclosure - Share Based Compensation - Outstanding and exercisable options (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails Share Based Compensation - Outstanding and exercisable options (Details) Details 33 false false R34.htm 40803 - Disclosure - Share Based Compensation - Non-vested share options (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails Share Based Compensation - Non-vested share options (Details) Details 34 false false R35.htm 40804 - Disclosure - Share Based Compensation - Weighted average assumptions for the options granted (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails Share Based Compensation - Weighted average assumptions for the options granted (Details) Details 35 false false R36.htm 40805 - Disclosure - Share Based Compensation - Recognized share-based compensation expense (Details) Sheet http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails Share Based Compensation - Recognized share-based compensation expense (Details) Details 36 false false R37.htm 40901 - Disclosure - Net loss per share (Details) Sheet http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails Net loss per share (Details) Details http://www.milestonepharma.com/role/DisclosureNetLossPerShareTables 37 false false R38.htm 41001 - Disclosure - Royalty Purchase Agreement (Details) Sheet http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails Royalty Purchase Agreement (Details) Details http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreement 38 false false All Reports Book All Reports mist-20230930.xsd mist-20230930_cal.xml mist-20230930_def.xml mist-20230930_lab.xml mist-20230930_pre.xml mist-20230930x10q.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mist-20230930x10q.htm": { "nsprefix": "mist", "nsuri": "http://www.milestonepharma.com/20230930", "dts": { "schema": { "local": [ "mist-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "mist-20230930_cal.xml" ] }, "definitionLink": { "local": [ "mist-20230930_def.xml" ] }, "labelLink": { "local": [ "mist-20230930_lab.xml" ] }, "presentationLink": { "local": [ "mist-20230930_pre.xml" ] }, "inline": { "local": [ "mist-20230930x10q.htm" ] } }, "keyStandard": 167, "keyCustom": 35, "axisStandard": 12, "axisCustom": 0, "memberStandard": 13, "memberCustom": 13, "hidden": { "total": 19, "http://xbrl.sec.gov/dei/2023": 7, "http://fasb.org/us-gaap/2023": 11, "http://www.milestonepharma.com/20230930": 1 }, "contextCount": 110, "entityCount": 1, "segmentCount": 26, "elementCount": 300, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 493, "http://xbrl.sec.gov/dei/2023": 32 }, "report": { "R1": { "role": "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_83M3Bb5VvkSsPDodRiYMUg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_83M3Bb5VvkSsPDodRiYMUg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss", "longName": "00200 - Statement - Condensed Consolidated Statements of Loss", "shortName": "Condensed Consolidated Statements of Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R5": { "role": "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity", "longName": "00300 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9mGJA3vkS9WVLqFbYA5A", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9mGJA3vkS9WVLqFbYA5A", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.milestonepharma.com/role/DisclosureOrganizationAndNatureOfOperations", "longName": "10101 - Disclosure - Organization and Nature of Operations", "shortName": "Organization and Nature of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.milestonepharma.com/role/DisclosureRevenues", "longName": "10301 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.milestonepharma.com/role/DisclosureShortTermInvestments", "longName": "10401 - Disclosure - Short-term Investments", "shortName": "Short-term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.milestonepharma.com/role/DisclosureDebt", "longName": "10501 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities", "longName": "10601 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.milestonepharma.com/role/DisclosureShareholdersEquity", "longName": "10701 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensation", "longName": "10801 - Disclosure - Share Based Compensation", "shortName": "Share Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.milestonepharma.com/role/DisclosureNetLossPerShare", "longName": "10901 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreement", "longName": "11001 - Disclosure - Royalty Purchase Agreement", "shortName": "Royalty Purchase Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "mist:RoyaltyPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "mist:RoyaltyPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.milestonepharma.com/role/DisclosureDebtTables", "longName": "30503 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "longName": "30603 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.milestonepharma.com/role/DisclosureShareholdersEquityTables", "longName": "30703 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables", "longName": "30803 - Disclosure - Share Based Compensation (Tables)", "shortName": "Share Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.milestonepharma.com/role/DisclosureNetLossPerShareTables", "longName": "30903 - Disclosure - Net loss per share (Tables)", "shortName": "Net loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSourcesOfLiquidityAndFundingRequirementsDetails", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details)", "shortName": "Summary of Significant Accounting Policies - Sources of Liquidity and Funding Requirements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "mist:SourcesOfLiquidityAndFundingRequirementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "mist:SourcesOfLiquidityAndFundingRequirementsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.milestonepharma.com/role/DisclosureRevenueDetails", "longName": "40301 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.milestonepharma.com/role/DisclosureDebtDetails", "longName": "40501 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_oJhXFTHlzkSCKRBktS2AkQ", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R26": { "role": "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "longName": "40502 - Disclosure - Debt - Convertible Note (Details)", "shortName": "Debt - Convertible Note (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_uJhEC91i2UGs7xV5kRAIAQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R27": { "role": "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "longName": "40503 - Disclosure - Debt - Total amount of interest cost (Details)", "shortName": "Debt - Total amount of interest cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_J-YH4n1fHk2XtVl41HyYXA", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "mist:ScheduleOfInterestCostOnDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_J-YH4n1fHk2XtVl41HyYXA", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "mist:ScheduleOfInterestCostOnDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "longName": "40601 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_tA5kVlhCH0i9paMCVliOBA", "name": "us-gaap:AccountsPayableTradeCurrent", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "longName": "40701 - Disclosure - Shareholders' Equity - Authorized share capital (Details)", "shortName": "Shareholders' Equity - Authorized share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_12_31_2022_q6Gd3TXZ_Eq_0hIQ1xNnXg", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_Gl_uWvtP_keN8hm2ObzcKw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R30": { "role": "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "longName": "40702 - Disclosure - Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details)", "shortName": "Shareholders' Equity - Pre-funded Warrants and Open Market Sale Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_9_30_2022_09t-wbyvyUmmwW3Uh5tkJw", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_22_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_Ax3Kk-ne3UKiTicav-rkmA", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_83M3Bb5VvkSsPDodRiYMUg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R31": { "role": "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "longName": "40703 - Disclosure - Shareholders' Equity - Additional paid-in capital (Details)", "shortName": "Shareholders' Equity - Additional paid-in capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2023_IJN-f_ugiUSSk1s-0jBBZg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "longName": "40801 - Disclosure - Share Based Compensation (Details)", "shortName": "Share Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_mist_RestatedShareOptionPlan2011Member_zGRN2V-SQEOv4yr_2kvrQw", "name": "mist:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedBecameAvailableForIssuance", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_mist_RestatedShareOptionPlan2011Member_zGRN2V-SQEOv4yr_2kvrQw", "name": "mist:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedBecameAvailableForIssuance", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails", "longName": "40802 - Disclosure - Share Based Compensation - Outstanding and exercisable options (Details)", "shortName": "Share Based Compensation - Outstanding and exercisable options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_lIRWURW0AkSO8U36sQeglw", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "longName": "40803 - Disclosure - Share Based Compensation - Non-vested share options (Details)", "shortName": "Share Based Compensation - Non-vested share options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_PlanNameAxis_mist_Plans2011And2019And2021InducementMember_vtluEGODo02SeXhBFRsyzA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_PlanNameAxis_mist_Plans2011And2019And2021InducementMember_vtluEGODo02SeXhBFRsyzA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails", "longName": "40804 - Disclosure - Share Based Compensation - Weighted average assumptions for the options granted (Details)", "shortName": "Share Based Compensation - Weighted average assumptions for the options granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "mist:Sharebasedcompensationarrangementbysharebasedpaymentawardgrantsinperiodweightedaveragefairvalueexerciseprice", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "mist:Sharebasedcompensationarrangementbysharebasedpaymentawardgrantsinperiodweightedaveragefairvalueexerciseprice", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails", "longName": "40805 - Disclosure - Share Based Compensation - Recognized share-based compensation expense (Details)", "shortName": "Share Based Compensation - Recognized share-based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_zd1wjKkOq0eRUb_ltlysWg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_nNJs8XEXFEWFvVNeFnbNrA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "unique": true } }, "R37": { "role": "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails", "longName": "40901 - Disclosure - Net loss per share (Details)", "shortName": "Net loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_zhZkx12Gc0CeyEXwdRXM5g", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_zhZkx12Gc0CeyEXwdRXM5g", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_t7aO3oS5jEeps8A6ujltpA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails", "longName": "41001 - Disclosure - Royalty Purchase Agreement (Details)", "shortName": "Royalty Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_3_27_2023_To_3_27_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_5khQMpcWhUGV5CIJl0uzxw", "name": "mist:FundingReceivedUponSaleOfProductRights", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "mist:RoyaltyPurchaseAgreementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_3_27_2023_To_3_27_2023_srt_CounterpartyNameAxis_mist_RtwInvestmentsLpMember_us-gaap_TypeOfArrangementAxis_mist_StrategicFinancingAgreementsMember_5khQMpcWhUGV5CIJl0uzxw", "name": "mist:FundingReceivedUponSaleOfProductRights", "unitRef": "Unit_Standard_USD_DfI4_xcFvUGIjbE1xFCoYg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "mist:RoyaltyPurchaseAgreementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "mist-20230930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits payable", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r69", "r179" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r101", "r159", "r160", "r390" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r293" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r93", "r103", "r104", "r110", "r116", "r123", "r131", "r132", "r147", "r151", "r153", "r155", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r265", "r268", "r269", "r281", "r282", "r300", "r307", "r324", "r356", "r373", "r374", "r397", "r408", "r409", "r421", "r435", "r448" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r424" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSourcesOfLiquidityAndFundingRequirementsDetails" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and short-term investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r434" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r120", "r121", "r122", "r145", "r298", "r318", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r357", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r415" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "positiveLabel": "Employee stock purchase plan purchases (in shares)", "terseLabel": "Number of shares issued under the ESPP", "verboseLabel": "Shares issued", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r5", "r46", "r47", "r73" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r425" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r41", "r451" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r5", "r46", "r47", "r73", "r237" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r424" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r117", "r118", "r180", "r209", "r295", "r392", "r393" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Cancellation of common shares (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r5", "r46", "r47", "r73" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r424" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r426" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life for vested options (in years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r249" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "terseLabel": "Schedule of outstanding and exercisable options", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r293" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r424" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Use of Accounting Estimates and Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r65" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r427" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r15" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r292" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r250" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted average assumptions for the options granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r79" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Schedule of non-vested share options activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r41", "r87", "r108", "r149", "r289", "r360", "r420", "r493" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r120", "r121", "r122", "r145", "r298", "r318", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r357", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r375", "r415" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRevenues" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Revenues", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r89", "r90", "r91" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r57", "r148" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r47" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r18" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r59", "r197", "r402", "r403" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r92", "r120", "r121", "r122", "r124", "r130", "r132", "r157", "r158", "r257", "r258", "r259", "r262", "r263", "r272", "r274", "r275", "r277", "r279", "r311", "r313", "r325", "r494" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Total interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r58", "r196", "r205", "r402", "r403" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r257", "r258", "r259", "r325", "r441", "r442", "r443", "r479", "r494" ] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r32" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r16", "r95", "r116", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r267", "r270", "r271", "r282", "r410", "r448", "r481", "r482" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Senior Secured Convertible Notes", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r68", "r177", "r178", "r188", "r189", "r190", "r194", "r195", "r196", "r197", "r198", "r399", "r400", "r401", "r402", "r403" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r133", "r225", "r431", "r432", "r444" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r92", "r105", "r106", "r107", "r120", "r121", "r122", "r124", "r130", "r132", "r145", "r157", "r158", "r222", "r257", "r258", "r259", "r262", "r263", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r283", "r284", "r285", "r286", "r287", "r288", "r294", "r311", "r312", "r313", "r325", "r375" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r125", "r126", "r127", "r128", "r129", "r136", "r138", "r139", "r140", "r144", "r280", "r281", "r299", "r309", "r395" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r133", "r225", "r431", "r444" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r236" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r2" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r255", "r260" ] }, "mist_DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the denomination of the principal amount of debt that is used in conversion calculations.", "label": "Debt Instrument, Principal Amount Denomination for Conversion Into Common Stock", "terseLabel": "Principal amount denomination for conversion" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r161", "r162", "r359" ] }, "mist_DebtInstrumentConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "DebtInstrumentConvertibleSharesIssuable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares to be issued on conversion of convertible debt.", "label": "Debt Instrument, Convertible, Shares Issuable", "terseLabel": "Convertible shares issuable" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Based Compensation" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "mist_PaymentsOfWarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "PaymentsOfWarrantIssuanceCosts", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow on payments of pre-funded warrant issuance costs", "label": "Payments Of Warrant Issuance Costs", "negatedLabel": "Pre-funded warrant issuance costs" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r162", "r359" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Nature of Operations" } } }, "auth_ref": [] }, "mist_DebtInstrumentPaidInKindInterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "DebtInstrumentPaidInKindInterestPayable", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of paid-in kind interest payable on debt.", "label": "Debt Instrument, Paid in Kind Interest Payable", "terseLabel": "Paid in kind (PIK) interest" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from convertible notes", "verboseLabel": "Proceeds from issuance of senior secured convertible debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r20" ] }, "mist_ScheduleOfInterestCostOnDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ScheduleOfInterestCostOnDebtTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest cost on debt instrument.", "label": "Schedule Of Interest Cost On Debt [Table Text block]", "terseLabel": "Schedule of total amount of interest cost" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Offering price", "verboseLabel": "Issuance of common shares, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r5", "r46", "r47", "r73", "r325", "r375", "r385", "r421" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r94", "r102", "r116", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r266", "r270", "r282", "r410", "r448", "r449", "r481" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Employee stock purchase plan purchases", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r5", "r46", "r47", "r73" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Estimated Fair Value", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Threshold Percentage of stock price", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding", "verboseLabel": "Number of warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "verboseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r5", "r19", "r73" ] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Cancellation of common shares", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r5", "r46", "r47", "r73" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued during the period", "verboseLabel": "Issuance of common shares, net of issuance costs (shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r5", "r46", "r47", "r73", "r319", "r375", "r385" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r38", "r394" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r39", "r42", "r451" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r70", "r115", "r206", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r220", "r222", "r278", "r378", "r379", "r386" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r81", "r97", "r116", "r147", "r152", "r154", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r266", "r270", "r282", "r302", "r348", "r410", "r422", "r448", "r449", "r481" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r62" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - End of period", "periodStartLabel": "Cash and cash equivalents - Beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r22", "r62", "r112" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r55", "r198", "r290", "r437" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r19", "r92", "r105", "r106", "r107", "r120", "r121", "r122", "r124", "r130", "r132", "r145", "r157", "r158", "r222", "r257", "r258", "r259", "r262", "r263", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r283", "r284", "r285", "r286", "r287", "r288", "r294", "r311", "r312", "r313", "r325", "r375" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common shares, net of issuance costs", "verboseLabel": "Net proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "mist_AggregateNetSalesAbove500MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AggregateNetSalesAbove500MillionMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to annual aggregate net sales above 500 million.", "label": "Aggregate Net Sales Above 500 Million [Member]", "terseLabel": "Above $500 million" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r424" ] }, "mist_PurchaseAndSaleAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "PurchaseAndSaleAgreementAbstract", "lang": { "en-us": { "role": { "documentation": "n/a.", "label": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "mist_RoyaltyPurchaseAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RoyaltyPurchaseAgreementTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about the royalty purchase agreement", "label": "Royalty Purchase Agreement [Table]" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r256" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "mist_RoyaltyPurchaseAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RoyaltyPurchaseAgreementLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Information about the royalty purchase agreement", "label": "Royalty Purchase Agreement [Line Items]", "terseLabel": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "mist_DebtInstrumentPaidInKindInterestTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "DebtInstrumentPaidInKindInterestTerm", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "The period during which interest to be paid in kind.", "label": "Debt Instrument, Paid In Kind Interest, Term", "terseLabel": "Paid in kind, term" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Shares", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r412", "r413", "r414", "r416", "r417", "r418", "r419", "r441", "r442", "r479", "r491", "r494" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "mist_RoyaltyPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RoyaltyPurchaseAgreementTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreement" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of information pertaining to purchase and sale agreement during the period of an entity.", "label": "Royalty Purchase Agreement [Text Block]", "terseLabel": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r61" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense related to debt", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r3" ] }, "us-gaap_CommonStockSharesAuthorizedUnlimited": { "xbrltype": "authorizedUnlimitedItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorizedUnlimited", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]", "terseLabel": "Common shares, Shares authorized (in shares)", "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\"." } } }, "auth_ref": [ "r18" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r17", "r24" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Closing balance", "periodStartLabel": "Opening balance", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r47", "r50", "r51", "r66", "r338", "r354", "r376", "r377", "r410", "r422", "r440", "r446", "r480", "r494" ] }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Short-term Investments" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, Shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r47" ] }, "mist_RequiredNoticeTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RequiredNoticeTerm", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The required notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Required Notice Term", "terseLabel": "Required notice (in days)" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r424" ] }, "mist_BeneficialOwnershipThreshold": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "BeneficialOwnershipThreshold", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum threshold of a beneficial owner upon exercise of the exchange agreement.", "label": "Beneficial Ownership Threshold", "terseLabel": "Maximum ownership after exercise of exchange agreement" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r111" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r7" ] }, "mist_StrategicFinancingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "StrategicFinancingAgreementsMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to strategic financing agreements.", "label": "Strategic Financing Agreements [Member]", "terseLabel": "Strategic Financing Agreements" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash provided by financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r111" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash provided by (used in) investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r62", "r63", "r64" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common shares, no par value, unlimited shares authorized 33,481,787 shares issued and outstanding as of September 30, 2023, 34,286,002 shares issued and outstanding as of December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r47", "r303", "r410" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r14", "r116", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r267", "r270", "r271", "r282", "r335", "r396", "r422", "r448", "r481", "r482" ] }, "mist_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledNumberOfShares", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Cancelled, Number of Shares", "negatedLabel": "Cancelled", "terseLabel": "Cancelled" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "mist_WarrantsIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "WarrantsIssuedDuringPeriodShares", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during period.", "label": "Warrants Issued During Period, Shares", "terseLabel": "Private placement (in shares)" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at the end of period (in shares)", "periodStartLabel": "Balance at the beginning of period (in shares)", "terseLabel": "Common shares, Shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r47", "r336", "r354", "r494", "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Total number of shares available for awards under the plan", "verboseLabel": "Number of common shares available for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r33" ] }, "mist_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageGrantDateFairValue", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options cancelled.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Cancelled, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "mist_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Warrants issued" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r239" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r238" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "mist_WeightedAverageNumberOfSharesAndPrefundedWarrantsOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "WeightedAverageNumberOfSharesAndPrefundedWarrantsOutstandingBasic", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "documentation": "Number of basic shares or units and pre-funded warrants, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time.", "label": "Weighted Average Number Of Shares And Prefunded Warrants Outstanding Basic", "terseLabel": "Weighted average number of shares and pre-funded warrants outstanding, basic" } } }, "auth_ref": [] }, "mist_CollaborationAndLicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "CollaborationAndLicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenues" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r246" ] }, "mist_Sharebasedcompensationarrangementbysharebasedpaymentawardgrantsinperiodweightedaveragefairvalueexerciseprice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "Sharebasedcompensationarrangementbysharebasedpaymentawardgrantsinperiodweightedaveragefairvalueexerciseprice", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information pertaining to fair value of exercise price", "label": "Exercise price" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r48", "r410", "r492" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "mist_RtwInvestmentsLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RtwInvestmentsLpMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to RTW Investments LP.", "label": "RTW Investments, LP" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Purchase price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "verboseLabel": "Number of options, Options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r232", "r233" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Share Based Compensation", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r74", "r75", "r76", "r77" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r232", "r233" ] }, "mist_WeightedAverageNumberOfSharesAndPrefundedWarrantsOutstandingDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "WeightedAverageNumberOfSharesAndPrefundedWarrantsOutstandingDiluted", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "documentation": "Number of diluted shares or units and pre-funded warrants, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time.", "label": "Weighted Average Number Of Shares And Prefunded Warrants Outstanding Diluted", "terseLabel": "Weighted average number of shares and pre-funded warrants outstanding, diluted" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r234" ] }, "mist_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossNonvested": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossNonvested", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period that are nonvested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross, Nonvested", "terseLabel": "Granted" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r52", "r83", "r305", "r410", "r440", "r446", "r480" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r234" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, and Shareholders' Equity" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "mist_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to employee stock purchase plan.", "label": "ESPP" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend (as a percent)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r252" ] }, "mist_InducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "InducementPlanMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to inducement plan.", "label": "2021 Inducement Plan" } } }, "auth_ref": [] }, "mist_CommonStockSharesWarrantExchanged": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "CommonStockSharesWarrantExchanged", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units for warrants exchanged.", "label": "Common Stock, Shares Warrant Exchanged", "terseLabel": "Common shares exchanged for pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility (as a percent)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r251" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r224", "r297", "r310", "r327", "r328", "r380", "r381", "r382", "r383", "r384", "r387", "r388", "r398", "r404", "r405", "r411", "r450", "r483", "r484", "r485", "r486", "r487", "r488" ] }, "mist_ThresholdAnnualAggregateNetSalesForFuturePaymentsCalculation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ThresholdAnnualAggregateNetSalesForFuturePaymentsCalculation", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The threshold amount of annual aggregate net sales for future payments calculation.", "label": "Threshold Annual Aggregate Net Sales for Future Payments Calculation", "terseLabel": "Threshold amount of annual aggregate net sales" } } }, "auth_ref": [] }, "mist_AccretionAmortizationExpenseOfInvestmentDiscountOrPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AccretionAmortizationExpenseOfInvestmentDiscountOrPremium", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount recognized for accretion or amortization of investment discount or premium.", "label": "Accretion Amortization Expense Of Investment Discount Or Premium", "terseLabel": "Accretion of investment discount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r253" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r223", "r224", "r251", "r252", "r253", "r296", "r297", "r310", "r327", "r328", "r380", "r381", "r382", "r383", "r384", "r387", "r388", "r398", "r404", "r405", "r411", "r414", "r447", "r450", "r484", "r485", "r486", "r487", "r488" ] }, "mist_Plans2011And2019And2021InducementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "Plans2011And2019And2021InducementMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information for 2011 Plan, 2019 Plan and 2021 Inducement Plans.", "label": "Plans 2011 and 2019 and 2021 Inducement [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r239" ] }, "mist_AdditionalFuturePaymentsOnProductSalesAsPercentOfAggregateNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AdditionalFuturePaymentsOnProductSalesAsPercentOfAggregateNetSales", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The additional future payments on product sales as percent of aggregate net sales.", "label": "Additional Future Payments on Product Sales, as Percent of Aggregate Net Sales", "terseLabel": "Additional future payment as a percentage of aggregate net sales" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Acquisition of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r237" ] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r10", "r11" ] }, "mist_DebtInstrumentCouponRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "DebtInstrumentCouponRatePercentage", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Coupon rate, under the debt agreement.", "label": "Debt Instrument, Coupon Rate Percentage", "terseLabel": "Coupon rate (as a percent)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.milestonepharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r1", "r7" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "totalLabel": "Total", "verboseLabel": "Senior secured convertible notes", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r9", "r82", "r189", "r204", "r400", "r401", "r490" ] }, "mist_FundingReceivedUponSaleOfProductRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "FundingReceivedUponSaleOfProductRights", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of funding received from the sale of product rights.", "label": "Funding Received Upon Sale Of Product Rights", "terseLabel": "Funding received from sale of product rights" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254" ] }, "mist_AggregateNetSalesUpTo500MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AggregateNetSalesUpTo500MillionMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to annual aggregate net sales up to 500 million.", "label": "Aggregate Net Sales Up to 500 Million [Member]", "terseLabel": "Up to $500 million" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted", "verboseLabel": "Weighted average exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r236" ] }, "mist_AggregateNetSalesUpTo800MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AggregateNetSalesUpTo800MillionMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to annual aggregate net sales up to 800 million.", "label": "Aggregate Net Sales Up to 800 Million [Member]", "terseLabel": "Up to $800 million" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r238" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r224", "r297", "r310", "r327", "r328", "r380", "r381", "r382", "r383", "r384", "r387", "r388", "r398", "r404", "r405", "r411", "r450", "r483", "r484", "r485", "r486", "r487", "r488" ] }, "mist_AggregateNetSalesAbove800MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AggregateNetSalesAbove800MillionMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to annual aggregate net sales above 800 million.", "label": "Aggregate Net Sales Above 800 Million [Member]", "terseLabel": "Above $800 million" } } }, "auth_ref": [] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureRevenueDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "verboseLabel": "Revenue", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r88", "r478" ] }, "mist_FuturePaymentsOnProductSalesAsPercentOfAggregateNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "FuturePaymentsOnProductSalesAsPercentOfAggregateNetSales", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The future payments on product sales as percent of aggregate net sales.", "label": "Future Payments on Product Sales, as Percent of Aggregate Net Sales", "terseLabel": "Future payment as a percentage of aggregate net sales" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r223", "r224", "r251", "r252", "r253", "r296", "r297", "r310", "r327", "r328", "r380", "r381", "r382", "r383", "r384", "r387", "r388", "r398", "r404", "r405", "r411", "r414", "r447", "r450", "r484", "r485", "r486", "r487", "r488" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Outstanding and exercisable options, weighted average exercise price" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r67", "r114", "r176", "r182", "r183", "r184", "r185", "r186", "r187", "r192", "r199", "r200", "r202" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Award, Tranche One", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instruments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r119", "r177", "r178", "r179", "r180", "r181", "r183", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r201", "r291", "r399", "r400", "r401", "r402", "r403", "r439" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r109", "r125", "r126", "r127", "r128", "r129", "r135", "r136", "r138", "r139", "r140", "r144", "r280", "r281", "r299", "r309", "r395" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r12" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r17", "r28", "r31", "r39", "r40", "r42", "r43", "r71", "r72", "r119", "r177", "r178", "r179", "r180", "r181", "r183", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r197", "r198", "r201", "r291", "r399", "r400", "r401", "r402", "r403", "r439" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r117", "r118", "r180", "r209", "r295", "r391", "r393" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs", "terseLabel": "Debt issuance costs paid", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Gross", "terseLabel": "Original principal", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r9", "r82", "r203" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r53", "r64", "r86", "r93", "r103", "r104", "r107", "r116", "r123", "r125", "r126", "r127", "r128", "r131", "r132", "r137", "r147", "r151", "r153", "r155", "r156", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r281", "r282", "r308", "r356", "r373", "r374", "r397", "r420", "r448" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development, net of tax credits", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r44", "r261", "r489" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r264" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property and equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r301", "r306", "r410" ] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Award, Tranche Two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term Investments.", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r84", "r85", "r433" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r56", "r358" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtConvertibleNoteDetails", "http://www.milestonepharma.com/role/DisclosureDebtDetails", "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails", "http://www.milestonepharma.com/role/DisclosureRoyaltyPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r264" ] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Share options", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r445" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Outstanding and exercisable options, number of shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities excluded from the computation of diluted weighted average shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r147", "r151", "r153", "r155", "r397" ] }, "mist_CommercialExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "CommercialExpense", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "documentation": "Expenses recognized in the period that are directly related to the commercial of products or services.", "label": "Commercial Expense", "terseLabel": "Commercial" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r65", "r113" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r23" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of additional paid-in capital", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r5" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSourcesOfLiquidityAndFundingRequirementsDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r49", "r73", "r304", "r314", "r315", "r323", "r337", "r410" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTotalAmountOfInterestCostDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r3", "r39", "r58", "r198" ] }, "mist_EquityIncentivePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "EquityIncentivePlan2019Member", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 2019 Equity Incentive Plan.", "label": "2019 Plan" } } }, "auth_ref": [] }, "mist_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageFairValuePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageFairValuePricePerShare", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsForOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average fair value price paid per share during the reporting period for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Fair Value Price Per Share", "terseLabel": "Share price (in dollars per share)" } } }, "auth_ref": [] }, "mist_PaymentsToSaleMaturityAndCollectionOfShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "PaymentsToSaleMaturityAndCollectionOfShortTermInvestments", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons", "label": "Payments To Sale Maturity And Collection Of Short term Investments", "negatedLabel": "Redemption of short-term investments" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r36", "r37", "r227" ] }, "mist_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedBecameAvailableForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedBecameAvailableForIssuance", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of options forfeited after termination of one plan became available in 2019 plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Forfeited, Became Available For Issuance", "terseLabel": "Number of options forfeited after termination of one plan" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation of property and equipment", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r3", "r150" ] }, "mist_SignificantRisksAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "SignificantRisksAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to significant risks and uncertainties.", "label": "Significant Risks and Uncertainties Policy [Policy Text Block]", "terseLabel": "Significant Risks and Uncertainties" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Non-vested share options at end of period", "periodStartLabel": "Non-vested at beginning of period", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested, outstanding", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityPreFundedWarrantsAndOpenMarketSaleAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r436" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt costs", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r198", "r290", "r402", "r403", "r437" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "negatedLabel": "Forfeited", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of Convertible Note", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net income (loss) per share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "mist_WarrantsIssuedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "WarrantsIssuedDuringPeriodValue", "crdr": "credit", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Value of warrants issued during period.", "label": "Warrants Issued During Period, Value", "terseLabel": "Private placement" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r25", "r26", "r27", "r28", "r29", "r30", "r31", "r71", "r72", "r73", "r98", "r99", "r100", "r146", "r207", "r208", "r209", "r211", "r214", "r219", "r221", "r319", "r320", "r321", "r322", "r404", "r430", "r438" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average fair value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Non-vested at end of period", "periodStartLabel": "Non-vested at beginning of period", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "mist_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "PreFundedWarrantMember", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to pre funded warrants.", "label": "Pre Funded Warrants", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAdditionalPaidInCapitalDetails", "http://www.milestonepharma.com/role/DisclosureShareholdersEquityAuthorizedShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Authorized share capital", "verboseLabel": "Additional paid-in capital", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r98", "r99", "r100", "r146", "r207", "r208", "r209", "r211", "r214", "r219", "r221", "r319", "r320", "r321", "r322", "r404", "r430", "r438" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, outstanding", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r406" ] }, "mist_SourcesOfLiquidityAndFundingRequirementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "SourcesOfLiquidityAndFundingRequirementsPolicyPolicyTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for sources of liquidity and funding requirements.", "label": "Sources of Liquidity and Funding Requirements Policy [Policy Text Block]", "terseLabel": "Sources of Liquidity and Funding Requirements" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Administration", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r54" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.milestonepharma.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r8" ] }, "mist_IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in operating lease right of use asset, net.", "label": "Increase Decrease In Operating Lease Right Of Use Asset, Net", "terseLabel": "Operating lease assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited", "documentation": "Weighted average grant-date fair value of non-vested options forfeited." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of shares to vest", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r452" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r256" ] }, "mist_TaxCreditsReceivableResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "TaxCreditsReceivableResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing research and development expenditures.", "label": "Tax Credits Receivable, Research and Development", "terseLabel": "Research and development tax credits receivable" } } }, "auth_ref": [] }, "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShortTermInvestments" ], "lang": { "en-us": { "role": { "label": "Investments and Other Noncurrent Assets [Text Block]", "terseLabel": "Short-term Investments", "documentation": "The entire disclosure for investments and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r22", "r96", "r389" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r134", "r141", "r142", "r143" ] }, "mist_IncreaseDecreaseInStockholdersEquityAndTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "IncreaseDecreaseInStockholdersEquityAndTemporaryEquityRollForward", "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Increase (Decrease) in Stockholders' Equity and Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "auth_ref": [] }, "mist_AccruedResearchAndDevelopmentLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "AccruedResearchAndDevelopmentLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research and Development Liabilities, Current", "terseLabel": "Accrued research and development liabilities" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Pre-funded warrants - 9,577,257 issued and outstanding as of September 30, 2023 and 8,518,257 as of December 31, 2022", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "mist_IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable", "crdr": "credit", "calculation": { "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.milestonepharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as research and development tax credits receivable.", "label": "Increase (Decrease) in Research and Development Tax Credits Receivable", "negatedLabel": "Research and development tax credits receivable" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r23" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Loss" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.milestonepharma.com/role/DisclosureOrganizationAndNatureOfOperations" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Nature of Operations", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r45", "r80", "r316", "r317" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.milestonepharma.com/role/DisclosureNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Share options", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r141" ] }, "mist_RestatedShareOptionPlan2011Member": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "RestatedShareOptionPlan2011Member", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationNonVestedShareOptionsDetails", "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationOutstandingAndExercisableOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to restated 2011 stock option plan.", "label": "2011 Plan" } } }, "auth_ref": [] }, "mist_CommercialActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.milestonepharma.com/20230930", "localname": "CommercialActivitiesMember", "presentation": [ "http://www.milestonepharma.com/role/DisclosureShareBasedCompensationRecognizedShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about commercial activities have been included.", "label": "Commercial activities" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r392": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r393": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r394": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r430": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r432": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 58 0001558370-23-018665-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-018665-xbrl.zip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𓣤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end